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ABSTRACT
The Diversity Found Among Carbapenem-Resistant Bacteria
Galen Edward Card
Department of Microbiology and Molecular Biology, BYU
Master of Science
This work will look at two factors that add to the diversity of carbapenem resistant
bacteria. First, it focuses on the diversity of carbapenemase resistance plasmids. 446 plasmids
were characterized by size, gene content and replicon groups. We identified that on average, over
30% of the encoded proteins on each plasmid have an unknown function. Plasmid sizes ranged
from 1.6kb to 500kb, with an average of around 100kb and median of 80kb. Additionally, six
replicon groups account for 80% of all the carbapenemase resistance plasmids. We also highlight
the lack of data available for carbapenemase carrying plasmids from bacterial genera other than
Escherichia and Klebsiella, and plasmids that carry the New Delhi metallo-β- lactamase or the
Verona-integron encoded metallo-β-lactamase.
Second, we characterized the β-lactamase diversity of a single carbapenemase resistant
Klebsiella pneumoniae. This isolate encodes six distinct β-lactamases, all of which are
functional, and three of which are redundant. Additionally, we determined that the CTX-M-15
cephalosporinase imparts a greater fitness when grown in aztreonam (a monobactam) than
ceftazidime (a cephalosporin). Finally, we show that individually, these β-lactamases do not
account for the elevated levels of resistance seen in the parent strain, indicating that the passive
resistance mechanisms (i.e. efflux pumps, altered membrane porins) may play a larger role than
originally thought.

Keywords: Antimicrobial resistance, β-lactamase, carbapenem resistant Enterobacteriaceae,
Klebsiella pneumoniae, Extended-spectrum β-lactamase, ESBL, plasmid, horizontal gene
transfer
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INTRODUCTION
The Rise of Antimicrobial Resistance
Since the dawn of the antimicrobial era in 1937 with the introduction of sulfonamides,
and the subsequent resistance of microbes arising in 1942, we have been in an arms race against
rapidly evolving bacteria (1). Like clockwork, with each implementation of a new antimicrobial,
resistance to that antimicrobial has appeared shortly thereafter (2). During the past several
decades we have seen the rapid emergence of multi-drug resistant (MDR) and pan-resistant
bacteria (3). With limited treatment options for these MDR organisms, and no treatments for
pan-resistant organisms, we are facing what is being called the post-antimicrobial era, a time in
which a seemingly routine infection presents the threat of death. Indeed, this threat is real with
fatality rates of certain MDR bacteria reaching 50% (4). Many factors play a part in the rise and
dissemination of antimicrobial resistance. The most important are the use of antimicrobials in
agriculture, the clinical misuse of antimicrobials, and the facile spread of resistance within a
bacterial population.
The use of antimicrobials in agriculture – What started as a prophylactic measure to
prevent loss of livestock and enhance weight gain of food animals has led to a burgeoning
healthcare crisis (5). Furthermore, it has been predicted that antibiotic use in agriculture will
increase by 67% from 2010 through 2030, despite the restrictions that have been placed on their
use in many countries (6). When antimicrobials are mixed in livestock feed, they quickly become
diluted as rain and runoff mixes with the feed. The diluted antimicrobial then reaches a subinhibitory concentration that doesn’t kill some bacteria. Instead, it creates a selective pressure
that kills a majority, allowing the few bacteria that can cope with the diluted antimicrobials
propagate (7-10). This leads to rapid mutation and evolution as the bacteria improve their
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resistance mechanisms to the antimicrobials. This then contributes to the human healthcare crisis
as the zoonoses found on farms enter the human population through contaminated food products
(11-13). Studies have shown that many species within the Enterobacteriaceae family that are
found on farms have also been found on hospital surfaces and isolated from infected patients
(14-17), giving credence to the threat posed to human health from the use of antimicrobials in
agriculture.
The clinical misuse of antimicrobials – The misuse of antimicrobials in a clinical setting
has two parts: the prescription of antimicrobials for a non-susceptible infection and prescribing a
prolonged antimicrobial regimen (2, 18-20). Since antibiotics have no effect on viral infections,
using them to treat viral infections only provides an opportunity to select for resistant isolates
and should not be done. Second, the World Health Organization has shown through current
research that prolonged courses of antimicrobials may increase the rates of antimicrobial
resistance (2, 21). This persistent exposure to antimicrobials provides an environment wherein
the bacteria have time to mutate and develop resistance to the antimicrobial. Proper antimicrobial
stewardship in the healthcare setting is essential if we are to slow the spread of resistance.
Spread of antimicrobial resistance within a bacterial population – The third, and perhaps
most important, factor that contributes to the rise and dissemination of antimicrobial resistance is
the facile transfer of antimicrobial resistance genes within a bacterial community. Many of the
antimicrobial resistance genes are found within mobile genetic elements such as plasmids and
transposons. Transposons, in their simplest form, are stretches of DNA that encode machinery
that can replicate, excise, and integrate these regions into other DNA sequences (22). Throughout
their “lifespan”, transposons can acquire genes from their host chromosome and transfer them to
plasmids (2, 18, 23-25). These genes can then be passed within a bacterial community as the
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plasmids are shared. The opposite can also occur. Resistance genes can be transferred from a
plasmid to the host’s chromosome. This is a permanent event. Once the resistance gene has
entered the chromosome, there is no straightforward way to eliminate the gene. On the other
hand, plasmids are more transient, and there are methods that can ‘cure’ bacterial strains of
plasmids (26-28). Figure 1 shows a possibility of how a transposon may acquire and transfer
resistance genes as it inserts and removes itself from the area surrounding the gene.
As mentioned, transposons can, and often do, integrate into plasmids. A plasmid is a circular
piece of extra-chromosomal DNA that is maintained and replicated along with the chromosome.
Ranging in size from less than 1kb to well over 200kb, they have the capability of carrying
numerous genes. These genes can fall into several categories ranging from basic housekeeping or
metabolism genes, to critical virulence genes, like the toxins responsible for the lethality of
Bacillus anthracis. One unique feature of some plasmids is that they also carry a cluster of tra
genes, or transfer genes. These genes provide a means for the plasmid to pass promiscuously
between strains of bacteria via horizontal transfer (2, 24). Plasmids can also carry genes that
cause the host bacterium to die if it does not retain the plasmid (29-32). These ‘plasmid addiction
systems’ function using a toxin/antitoxin strategy. Encoded on the plasmid is a toxin, and its
corresponding antitoxin. Of these two protein products, the toxin component is more stable. If
the plasmid is lost from the host strain, the levels of antitoxin within the cytoplasm will decrease
as it degrades quicker than the toxin. This in turn leaves the toxin free to exert its lethal effects
within the cell. All these mechanisms contribute to the facile spread and maintenance of
antimicrobial resistance among bacterial populations.
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FIGURE 1: Acquisition of antibiotic resistance gene within a transposable element.
1) Wild type DNA receives transposon. 2) A transposition event occurs, leaving a scar upstream
of an antibiotic resistance gene as the transposon jumps downstream. 3) A second transposition
event leads to two possible scenarios where the antibiotic resistance gene is transferred to
another mobile genetic element such as a plasmid. Other recombination events are possible;
however, they do not transfer the antibiotic resistance to the new DNA.

4

β-lactams and Their Hydrolases
The most widely known class of antibiotics and one for which resistance has become a
grave issue due to the reasons mentioned, are the β-lactams. So named due to the presence of a
β-lactam ring as the central chemical backbone, these antibiotics have a four-membered ring, as
depicted in Figure 2. Table 1 lists the four classes of β-lactams and provides examples of each.
The first β-lactam antibiotic is also the original antibiotic discovered, penicillin. Penicillin and its
derivatives, along with all β-lactams employ the same mode of action to kill bacteria. Known as
cell wall inhibitors, β-lactams bind to and inactivate the penicillin-binding protein. This protein,
so named for penicillin’s action against it, is responsible for covalently cross-linking
peptidoglycan during bacterial cell wall synthesis. Without cross-linked peptidoglycan, cell
morphology becomes more elongated, cell structure is fragile, and bacterial lysis occurs in most
environments as water rushes into the cell to balance osmolarity. However, as with all
antibiotics, bacterial resistance to β-lactams quickly arose after their discovery.
This resistance is mediated by a β-lactam specific hydrolase, or a β-lactamase, of which
there are several types and various classification schemes. The simplest classification was
implemented by Ambler in 1980, in which β-lactamases were grouped based on protein sequence
(33). His scheme divides the β-lactamases into four classes, Ambler Classes A through D.
Classes A, C, and D are serine-mediated β-lactamases (34). The class B β-lactamases are
metallo-β-lactamases (MBLs) and require a zinc ion to assist in the hydrolysis reaction (35).
Figure 3 (adapted from original (36)) depicts how a serine β-lactamase catalyzes the
hydrolysis of a β-lactam. First, a serine residue of the β-lactamase will attack the carbonyl,
pushing electrons of the double bond onto the oxygen (Step 1). This leaves a highly unstable
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TABLE 1: The four classes of β-lactam antibiotics and examples of each.
β-lactam Antimicrobials
Penicillin
Aminopenicillin
Penicillins

Carboxypenicillin
Penicillinaseresistant penicillin

Monobactams

Aztreonam
st

1 Generation

2nd Generation
Cephalosporins

3rd Generation

4th Generation
Carbapenems

Imipenem
Doripenem
Ertapenem
Meropenem

Penicillin G
Penicillin V
Ampicillin
Amoxicillin
Carbenicillin
Ticarcillin
Methicillin
Nafcillin
Oxacillin
Cloxacillin
Cephalothin
Cephalexin
Cefazolin
Cefamandole
Cefaclor
Cefuroxime
Cefoxitin
Cefotetan
Ceftriaxone
Ceftazidime
Cefotaxime
Ceftozominem
Ceftibuten
Cefepime
Cefpirome
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FIGURE 2: The four classes of β-lactam antibiotics.
The core β-lactam is highlighted in red. Each derivative within each class will deviate in the R
groups. When hydrolyzed, the bond between the nitrogen and the carbonyl carbon is cleaved. A
few examples are given.
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negatively charged oxygen. To reduce this strain, the electrons collapse back down, and orbital
resonance dissipates the energy across the molecule, opening the β-lactam ring in the process
(Step 2). Then a two-step proton transfer from water to the serine residue of the β-lactamase
resolves the hydrolysis reaction (Steps 3-5).
The most commonly encountered β-lactamases are the class A β-lactamases TEM (named
for the patient in which it was first identified, Temoniera) and SHV (sulfhydryl variable) types,
with 90% of the ampicillin resistance encountered in E. coli mediated by TEM-1 (18). And due
to their widespread prevalence, β-lactamase inhibitors have been developed. These inhibitors do
not affect the activity of penicillin binding protein, and administration of these in conjunction
with a β-lactam can kill the bacteria. However, these inhibitors are only effective against the
serine mediated β-lactamases, exhibiting no effect on the class B MBLs due to their use of zinc
ions in the hydrolysis reaction (37, 38).
Extended-Spectrum β-lactamases – One cause of multi-drug resistant bacteria is due to
the emergence of extended-spectrum β-lactamases (ESBLs). Many of these ESBLs are from the
Ambler Class A and are derivatives of TEM and SHV type β-lactamases (2, 33). More
specifically, ESBLs are classified as oxyimino-cephalosporinases (2, 23), and are able to
hydrolyze penicillin as well as cephalosporins such as ceftazidime and cefepime (Table 1). Many
of these ESBLs have arisen due to only a few point mutations in either TEM or SHV βlactamases (2, 39, 40). These point mutations alter the active site of the β-lactamase enough to
accept a diverse range of β-lactams. However, they have also been shown to increase their
susceptibility to β-lactamase inhibitors such as clavulanate; but of course, additional mutations
can make them resistant (2, 38, 41). Figure 4 shows an example of the mutations that lead from
TEM-1 to several ESBL TEM variants (2).
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FIGURE 3: β-lactamase mediated hydrolysis of a cephalosporin.
A serine residue of the β-lactamase will attack the carbonyl, pushing electrons of the double
bond onto the oxygen (Step 1). This leaves a highly unstable negatively charged oxygen. To
reduce this strain, the electrons collapse back down, and orbital resonance dissipates the energy
across the molecule, opening the β-lactam ring in the process (Step 2). Then, a two-step proton
transfer from water to the serine residue of the β-lactamase resolves the hydrolysis reaction
(Steps 3-5). [36] (Adapted from original.)
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FIGURE 4: ESBL variants of TEM-1.
The common mutations among ESBL variants of TEM-1 are listed. The amino acid numbering is
according the conventions set forth by Ambler. *TEM-2 is not an ESBL, but several ESBLs are
derivates of TEM-2. **TEM-50 and TEM-68 are resistant to β-lactamase inhibitors. [2]
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Carbapenems and Their Hydrolases
In another effort to avoid the havoc wrought by β-lactamases on the efficacy of these
antibiotics, an additional class of β-lactams (carbapenems) was discovered. Because resistance to
carbapenems is very infrequent, they are used as a last resort for treating infections to avoid the
development of resistance. However, resistance to carbapenems developed anyway. Currently
there are about nine diverse types of carbapenemases falling into Ambler Classes A, B, and D
(42, 43). Each of those nine types have several variations. We will focus on four clinically
relevant types found in Enterobacteriaceae, the Class A serine-mediated Klebsiella pneumoniae
carbapenemase (KPC), and the three Class B metallo-β-lactamases (MBL): The New Delhi MBL
(NDM), the Verona integron-encoded MBL (VIM), and the Imipenem resistant Pseudomonastype MBL (IMP).
Klebsiella pneumoniae carbapenemase – First identified in 2001 (44), KPC was not the
first carbapenemase, as several MBLs that could hydrolyze carbapenem had already been
identified in Japan in the 1990’s (45). This initial variant (KPC-1) provided resistance to many of
the β-lactams, including all the cephalosporins and aztreonam, and was also resistant to the βlactamase inhibitors clavulanic acid and tazobactam (44). A recent review indicates that there are
currently 12 reported variants of the KPC enzyme (46). While KPC may not be the first
carbapenemase identified, it is the most common in the United States. As of February 27, 2018
the Centers for Disease Control and Prevention (CDC) report that KPC positive infections have
been reported from all 50 states and the District of Columbia (47). KPC enzymes have also been
reported from many other nations and in numerous gram-negative species, including
Acinetobacter baumanii, Pseudomonas aeruginosa, and nearly all the Enterobacteriaceae (4850).
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New-Delhi metallo-β-lactamase – Originally isolated from India in 2008, there are
currently more than ten reported variants of NDM (51). It is present in 34 states (47) and
multiple countries including the United Kingdom, Pakistan, India, Sweden and others (50). The
NDM carbapenemases have shown greater affinities for the penicillins, cephalosporins, and a
few of the carbapenems than the VIM and IMP carbapenemases (43). Additionally, a minimum
inhibitory concentration assay when NDM is cloned into susceptible strains show it conferring
high levels of resistance to penicillins (>256 μg/mL), cephalosporins (>256 μg/mL), the
monobactam aztreonam (>24 μg/mL), and all of the carbapenems (>16 μg/mL) (43), but other
reports indicate that NDM cannot hydrolyze aztreonam and, as a MBL, it is resistant to βlactamase inhibitors (52).
Verona integron-encoded metallo-β-lactamase – VIM has 14 reported variants with
amino acid content varying up to 10% (51). VIM originated from Pseudomonas aeruginosa in
the Mediterranean in 1997, but quickly spread into Enterobacteriaceae and proceeded to spread
globally. Reports indicate that VIM can hydrolyze all β-lactams except monobactams and, as an
MBL, it is resistant to β-lactamase inhibitors like clavulanate as tazobactam (53). Like the other
carbapenemases, plasmids are the primary mechanism for horizontal gene transfer of this
carbapenemase. According to the CDC, only 11 states have reported VIM positive infections
(47).
Imipenem resistant Pseudomonas metallo-β-lactamase – IMP shares many of the same
characteristics as VIM, but the amino acid content between the two diverges by 70% (51). IMP
also represents the most diverse type of carbapenemase with 18 variants reported (51). Isolated
in 1991 in Japan from Pseudomonas, it is the earliest carbapenemase discovered of the four, and
is resistant to the inhibitor clavulanic acid (54). Currently, IMP has been found in many of the
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enteric organisms, including Serratia, Providencia, and Klebsiella. As of February 2018, 13
states have reported IMP positive infections (47). As with many of the other carbapenemases,
IMP has the ability to hydrolyze many of the β-lactams, but it cannot hydrolyze the
monobactams (55).
Summary
While it is evident that much has been reported on the carbapenemases themselves, there
is a distinct lack of published papers characterizing the diversity of plasmids that carry one of
these four carbapenemases. Additionally, many of the reviews cited here mention that these
carbapenemase-resistance plasmids carry multiple β-lactamases, but the relationship and
interplay between the β-lactamases on a single plasmid is not well understood. The following
two chapters will clarify these two points.
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CHAPTER 1
Characterization of Carbapenemase-Resistance Plasmids
Galen E. Card, Brandon D. Pickett, Perry G. Ridge, Richard A. Robison
ABSTRACT
Carbapenem-resistant bacteria have quickly become a critical concern in nosocomial
infections. In treating these infections, a rapid diagnosis is crucial. Current practices may take up
to 76 hours, by which time the infection may become systemic, and the mortality rate is near
50%. To aid in carbapenemase understanding and detection, this report characterizes the gene
content and replicon types of 446 carbapenemase-carrying plasmids available in GenBank and
identifies the six most prevalent replicon types among these plasmids. The importance of this
work is twofold: First, there is no published work that characterizes the plasmids that carry some
of the most threatening antibiotic resistance genes, the carbapenemases. Having this information
available can aid in knowing where efforts need to be placed to complete our understanding of
these plasmids. Second, it highlights challenges that must be overcome if we are to adequately
diagnose and restrict the spread of these plasmids.
Key words: Plasmid, Antimicrobial resistance, Carbapenemase, Enterobacteriaceae
BACKGROUND
Nosocomial infections have quickly become a significant cause of mortality. In 2002, the
US Centers for Disease Control and Prevention estimated that the national mortality rate due to
hospital acquired infections was 5.8% (56). In 2011, that rate increased to 10.4% (57). While
these same reports show that the chance of acquiring an infection at the hospital has decreased,
the infections are becoming more lethal.
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One significant reason for this increase in mortality is the acquisition of antibiotic
resistance in bacterial populations (25). Bacterial strains such as the carbapenem resistant
Enterobacteriaceae (CREs), and multi-drug resistant Pseudomonas aeruginosa present
diagnostic challenges which in turn lead to poor prognoses. Treatment of these bacterial
infections usually begins with the administration of standard antibiotic regimens. The
ineffectiveness of the initial treatment is usually apparent within 24-48 hours. At this time, the
physician needs to reevaluate, order additional antibiotic susceptibility tests, and administer a
more advanced antibiotic regimen. This new treatment may include carbapenem antibiotics. For
resistant Enterobacteriaceae and Pseudomonas, this is an additional, ineffective 24-48-hour
period before it is apparent that the patient’s condition is not improving. At this time, about 76
hours after initial diagnosis, the infection may have become systemic. Once a CRE infection has
become systemic, the mortality rate is near 50% (58).
Antibacterial resistance is usually conferred to these organisms through mobile genetic
elements, predominately extra-chromosomal DNA called plasmids (25). Plasmids often carry the
molecular machinery to replicate themselves. This machinery allows for the transfer of the
plasmid between different bacterial strains, and sometimes between any gram-negative bacteria
(24). Furthermore, the antibiotic resistance genes on the plasmid can be located within a
transposable element. This transposable element has the potential to replicate and integrate itself
into new DNA sites, increasing the rate of spread (59). Additionally, many carbapenemasecarrying plasmids are large; therefore, they often carry a toxin/antitoxin plasmid addiction
system to prevent the bacterium from losing the plasmid (31).
To assist in the identification and treatment of drug resistant infections, a better
understanding of these carbapenemase carrying plasmids is needed. This brief report is the first

15

large-scale attempt to characterize the diversity of plasmids carrying carbapenemases from the
Klebsiella pneumoniae-producing carbapenemase (KPC), the New-Delhi metallo-β-lactamase
(NDM), the Verona-integron encoded metallo-β-lactamase (VIM), and the IMP-type metallo-βlactamase (IMP) families in seven clinically-relevant gram-negative bacteria (Enterobacter
aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Pseudomonas
aeruginosa, Providencia stuartii, and Serratia marcescens).
METHODS
Sequence acquisition
532 complete plasmid sequences were obtained from GenBank by a discontiguous
megablast nucleotide search (60) of four representative carbapenemase genes (IMP, KPC, NDM,
VIM, Supplementary File 1) to allow for variations within the carbapenemase family. We
employed the same Entrez strategy to filter for complete plasmids as used by Orlek et al. (61):
“biomol_genomic[PROP] AND plasmid[filter] NOT complete cds[Title] NOT
gene[Title] NOT genes[Title] NOT contig[Title] NOT scaffold[Title] NOT whole
genome map[Title] NOT partial sequence[Title] NOT partial plasmid[Title] NOT
locus[Title] NOT region[Title] NOT fragment[Title] NOT integron[Title] NOT
transposon[Title] NOT insertion sequence[Title] NOT insertion element[Title]
NOT phage[Title] NOT operon[Title]”
This blast search was done separately for the seven organisms of interest: Enterobacter
aerogenes, Enterobacter cloacae, Escherichia coli, Klebsiella pneumoniae, Pseudomonas
aeruginosa, Providencia stuartii, and Serratia marcescens. GenBank files were downloaded for
each blast alignment that scored >80% identity and query coverage. These sequences were
retrieved on 5 March 2018.
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Plasmid gene composition
A list of key terms was derived by a manual survey of 10% of the acquired GenBank
files, with cross reference to QuickGO, the European Bioinformatics Institute’s Gene Ontology
reference database (62), to classify gene products into one of the following categories: (a)
Antimicrobial resistance, with β-lactamases as a subset, (b) Plasmid transfer genes, (c)
Toxin/antitoxin systems, (d) DNA maintenance, modifying, and repair proteins, (e) Mobile
genetic elements, (f) Hypothetical genes, and (g) other. See Appendix A for the list of key terms.
Incompatibility group/Replicon typing and plasmid characterization
Plasmid incompatibility groups were determined by nucleotide BLAST (60, 63) against a
local download of the PlasmidFinder v1.3 Enterobacteriaceae database (64) downloaded on 1
March 2018. The incompatibility groups were assigned when matches met the following criteria:
(a) >=80% identity, (b) >=60% subject coverage, and (c) within 1% of the percent identity of the
highest match. Accordingly, more than one incompatibility group could be reported for any
given plasmid. Further characterization was accomplished as follows: (a) extracting the CDS
regions for each plasmid, (b) searching these CDS regions for key terms using regular
expressions, and (c) combining the results for plasmid groups of interest (e.g., those that belong
to Enterobacteriaceae). Please see Appendix B for a more detailed description. This
characterization of each plasmid and of groups of plasmids was accomplished using custom
scripts, made freely available at https://github.com/ridgelab/plasmidCharacterization.
Statistical analyses
Since plasmid length distributions are not normal (left-skewed), all statistical analyses
were performed with the Mann-Whitney U-test or the Kruskal-Wallis ranked ANOVA where
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appropriate, for non-parametric distributions. In an effort to be conservative, statistical
significance was determined if P<0.0001.
RESULTS
Plasmid gene composition
Due to the inherent inconsistencies of GenBank record annotations, our search method
required discarding 86/532 accessions, leaving a total of 446 accessions in this analysis
(accession numbers available in Appendix C). The criteria for keeping an accession in the
analysis was if at least one and no more than six carbapenemase genes were identified on the
plasmid. Of those 446 plasmids, 198 carry KPC, 168 carry NDM, 49 carry IMP, and 31 carry
VIM. When divided by species, 7 belong to E. aerogenes, 33 to E. cloacae, 142 to E. coli, 235 to
K. pneumoniae, 18 to P. aeruginosa, 3 to P. stuartii, and 8 to S. marcescens. The mean size of all
carbapenemase-carrying plasmids was 104,222 bp, with a median length of 87,663 bp. The
largest plasmid was 500,840 bp and the smallest, 1,635 bp. The average percent gene content of
all plasmids was as follows: Antimicrobial resistance genes, 8.0%; Plasmid transfer genes,
15.8%; DNA modification genes, 14.7%; Mobile genetic elements, 9.3%; Hypothetical genes,
33.2%; Other/Metabolic genes, 18.9% (Figure 4A). The plasmids carried, on average, ~2 βlactamases, with 22.6% of the plasmids carrying three or more, and the most β-lactamases on a
single plasmid being six. The carbapenemase copy number of these plasmids ranged from 1-3,
with 97.98% of the plasmids harboring only one carbapenemase.
When comparing certain plasmid features such as the presence or absence of plasmid
addiction systems (236/446 or 52.9% of plasmids contain one), polymerase genes, or the family
of carbapenemase on the plasmid to plasmid length, the average length of plasmids that carry
addiction systems and polymerases are significantly larger than those that do not (Mann-Whitney
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FIGURE 5: Characteristics of carbapenemase-encoding plasmids.
A) Mean percent gene content of all plasmids. B) Relationship between characteristics of interest
and plasmid length. C) Relationship between species and plasmid length. D) Relationship
between incompatibility group and plasmid length, Significance is determined against the
average size of all plasmids. B-C) Mann-Whitney U-test, D) Kruskal-Wallis ranked ANOVA.
**** P<0.0001. All error bars indicate the 95% CI.
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U-test, P<0.0001, Figure 4B) and the average length of plasmids that carry KPC are
smaller than those that carry IMP (Kruskal-Wallis ranked ANOVA, P<0.05, Figure 4B).
However, removing an unusually large IMP plasmid (>500 kb) from this dataset eliminated this
significance. When observing average plasmid length by species, the only near-significant
difference was observed between E. coli and K. pneumoniae, with the latter being larger
(P=0.0018, Figure 4C). It is important to note that these two species also represent most of the
plasmids analyzed (377/446 or 84.5%).
Plasmid Incompatibility group/Replicon typing
No incompatibility group presented itself as the most abundant; however, the following
six groups constitute 80.27% of the plasmids: IncA/C (53/446 or 11.88%), IncFIB (57/446 or
12.78%), IncFII (88/446 or 19.73%), IncN (61/446 or 13.68%), IncR (40/446 or 8.97%), and
IncX3 (59/446 or 13.23%) (see Appendix D). Notably, 7.62% (34/446) of the plasmids could not
be accurately typed using this method. 58 plasmids carried more than one replicon, and these
were significantly larger than those that carried a single replicon (Mann-Whitney U-test
P<0.0001, data not shown). Additionally, the following incompatibility groups were found to
have an average length statistically different (Kruskal-Wallis ranked ANOVA, P<0.0001) than
the average of all plasmids: IncA/C2, IncFIB, IncHI1B, and IncX3 (Figure 4D). Figure 5 shows
the relative abundance of each incompatibility group among plasmids that carry the same family
of carbapenemase (full dataset available, Appendix E).
DISCUSSION
One of the most notable findings of this study was the amount of hypothetical and
uncharacterized genes found on these plasmids. It is possible that many of these genes may be
phage derived. This is of great concern when considering phage therapy as an alternative to
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FIGURE 6: Relative abundance of incompatibility groups among plasmids.
Predominant incompatibility groups from each carbapenemase family: KPC, IncFIB 18.2%,
IncFII 20.2%, IncN 17.7%, and IncR 13.6%; NDM, IncA/C2 17.9%, IncFIB 10.7%, IncFII
28.0%, and IncX3 29.2%; IMP, IncA/C2 22.4%, IncL/M 10.2%, IncN 34.7%, and NA 16.3%;
VIM, IncA/C2 16.1%, IncN 12.9%, IncR 12.9%, and NA 35.5%.
Note: Percent totals are larger than 100% because some plasmids have multiple replicon types.
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antibiotics. With potentially large regions of homology to phage genomes, a phage may
incorporate into these plasmids through homologous recombination. Then, as the recombinant
phage genome is packaged into the progeny phage, it may be possible that carbapenemases could
be included, resulting in a replication-deficient phage vector capable of transferring a
carbapenemase to a new bacterium through transduction. Before phage therapy of these
organisms is seriously pursued, this concept should be investigated so that another mechanism of
resistance transfer is not potentiated, as it has been shown for phage and other virulence genes
(65).
Additionally, for non-amplification, DNA-based identification of carbapenemase
production, it is important to realize that the plasmids of interest are quite large. With their
median length over 80 kb, plasmid isolation becomes difficult if necessary for the application,
and many of the replicon types identified are for low-copy number plasmids. This also
compounds the difficulties when detecting carbapenemase gene presence from a whole-blood
specimen, where concentrations are around 10 CFU/mL. This results in approximately 10 copies
of an ~800 bp gene that needs to be identified amongst the millions of base pairs in a milliliter of
blood.
Finally, this report has identified a few potential targets to slow the spread of
carbapenemase plasmids. First, the antitoxin of the plasmid addiction system could be targeted
(31). Doing so could prevent its binding with the toxin, resulting in the death of the host
harboring the plasmid. Second, 90.4% (403/446) of the plasmids carry transfer genes to pass the
plasmid between bacteria. Preventing pilus formation could dramatically reduce the spread of
these plasmids. This method is currently being pursued by several groups and include strategies
such as bacteriophage, colloidal clays, and antibodies (66). Finally, many of the plasmids carry a
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plasmid partitioning system, responsible for ensuring that each daughter receives a copy of the
plasmid. Targeting the motor or the partition-site binding protein of these systems, in
conjunction with the toxin/antitoxin system, could dramatically reduce the spread and persistence
of these plasmids in the hospital. These treatments could be used in a sterilization bath for
medical equipment prior to traditional sterilization techniques.
In conclusion, there is an abundance of data for the commonly encountered KPC and
NDM carbapenemases from K. pneumoniae and E. coli, and several non-traditional avenues that
may be pursued to help stop the spread of these resistance plasmids. However, this report is
lacking data for many of the other species, and for the VIM and IMP carbapenemases. Therefore,
a greater surveillance of the other species and carbapenemases is needed. P. aeruginosa is a
bacterium where much more data is needed to accurately characterize the diversity of
carbapenemase-carrying plasmids in this highly significant pathogen.
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CHAPTER 2
β-lactamase Diversity of a Single, CarbapenemResistant Enterobacteriaceae Isolate
Galen E. Card, Joel S. Griffitts Ph.D., Joshua D. Urquiaga, Richard A. Robison Ph.D.
ABSTRACT
Antibiotic resistance is quickly becoming an urgent problem in health care. One class of
antibiotics, the -lactams, has become severely compromised by emerging resistance. Resistance
to last-resort β-lactams (the carbapenems) is quickly spreading across the globe. We investigated
a carbapenem-resistant isolate of Klebsiella pneumoniae possessing six β-lactamase genes:
CMY-6, CTX-M-15, NDM-4, OXA-1, SHV-11, and TEM-1. Each of these genes was
functionally characterized in Escherichia coli using 5 β-lactam antibiotics (ampicillin,
carbenicillin, ceftazidime, aztreonam, and imipenem). These tests revealed distinct as well as
overlapping functions. Most notably, we observed that the carbapenemase NDM-4 provides a
greater fitness advantage when grown in a cephalosporin than the cephalosporinase CTX-M-15.
Also, we provide evidence that a sizable portion of the resistance that this strain of Klebsiella
exhibits against aztreonam and imipenem is not enzyme mediated.
INTRODUCTION
To date, there are about 20 different derivates of β-lactam antibiotics approved for
therapeutic use. Many of these antibiotics have been put on the World Health Organization’s
‘WATCH GROUP’, due to the higher potential for resistance among bacterial populations [1]. βlactam antibiotics fall into four broad classes; penicillins, cephalosporins, monobactams, and
carbapenems, each class representing several clinically important structural derivatives (Fig. 1).
With such a wide variety of β-lactams available, most infections can be treated effectively with
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these antibiotics. However, the mortality rate from nosocomial infections has been on the rise [2,
3] due to the increased incidence of multi-drug resistant infections [4, 5].
Many genera of the Enterobacteriaceae family have recently joined this class of multidrug resistant bacteria [6, 7] as they have acquired genes encoding extended-spectrum βlactamases (ESBL) and carbapenemases (carbapenem resistant Enterobacteriaceae, CRE). Septic
infections with ESBL or CRE strains of Klebsiella pneumoniae have a mortality rate of near 50%
[5].
We have in our collection various CRE isolates possessing 1-6 β-lactamase (bla) genes.
In this work, we characterize one of these isolates (Klebsiella pneumoniae strain 1300761), a
CRE isolate from which we have identified six distinct bla genes: CMY-6, CTX-M-15, NDM-4,
OXA-1, SHV-11 and TEM-1. Of these, five belong to the Ambler class A or C, designated as
serine mediated hydrolases, with the exception being NDM, which belongs to class B, the
metallo-β-lactamases which require zinc ions in the active site to catalyze the reaction [8]. Three
of them are recognized as ESBLs (CMY-6, CTX-M-15, and NDM-4,) and three are narrowspectrum β-lactamases (OXA-1, SHV-11, and TEM-1). While hydrolytic activity of these bla
genes is well documented through MICs, the in vivo fitness advantage provided by them by
analyzing growth kinetics is not. In this study, we use a standardized susceptible E. coli strain to
test resistance conferred by each of these bla genes, in response to challenge by five different βlactam antibiotics. Our observations shed light on the relative contributions of each gene and
contribute to our understanding of how multi-gene β-lactamase arsenals may function along with
alternative resistance mechanisms to provide strong β-lactam resistance in CRE strains.
ΜΕTHODS
Genome sequencing, assembly, and annotation
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Genome sequencing and read processing
A carbapenem resistant Klebsiella pneumoniae isolate was obtained from the Centers for
Disease Control and Prevention (K. pneumoniae 1300761) and DNA was extracted following the
recommended protocol for the MagNA Pure LC system (Roche Life Sciences). DNA was
quantified by fluorometry and 2μg was submitted to the BYU DNA Sequencing Center for
250bp paired end reads on an Illumina HiSeq 2500. Low complexity reads were filtered using
PRINSEQ version 0.20.4 [9] and adapter sequence removal and quality trimming was
accomplished using Trim Galore! version 0.4.3 with a phred score cutoff of 28. An additional
10bp were trimmed from the 5’ end of each read. All reads shorter than 150 bp were then
discarded and if their paired read was longer than 150 bp and passed the other quality checks,
they were retained as a singleton for use in assembly. Read quality statistics were then assessed
using FastQC version 0.11.4 [10].
Genome assembly and annotation
The reads were assembled using the St. Petersburg Assembler (SPAdes) version 3.10.1
[11]. K-mer values of 21, 33, 55, 77, 99, 129 were used for the assembly iterations. Assembly
statistics were compiled using QUAST version 4.0 [12]. Gene annotation was undertaken using
Prokka version 1.12 [13].
β-lactamase cloning
TABLE 2 contains primer pairs used to introduce restriction sites, a synthetic ribosome
binding site, and amplify the corresponding β-lactamases from K. pneumoniae 1300761. Each
bla gene was individually cloned into pJG780 with XbaI/SalI restriction sites (plasmid sequence
available in supplemental file 1) and transformed into NEB5-alpha (New England BioLabs), a
DH5-alpha derivative, following the manufacturer’s provided protocol with a recovery
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incubation of 90 minutes. The β-lactamase expression is under the control of a rhamnoseinducible promoter. Each clone was then sequence verified using the following plasmid specific
sequencing primer: CTGTCAGTAACGAGAAGGTCG. The resulting strains were named using
the following convention: Host vector_bla (i.e. E. coli pJG780_CMY-6) and are referred to by
the β-lactamase they produce (E. coli pJG780_CMY-6 is referred to as CMY-6)
Growth curve analysis
A single colony of the β-lactamase clones were grown in 5 ml of LB containing 30
μg/mL of kanamycin to ensure plasmid retention for 12-18 hours. Then, 100 μL was inoculated
in a 5 mL 1-hour subculture containing 30 μg/mL kanamycin and 0.3% rhamnose to induce βlactamase expression. Microtiter plates (96-well) were loaded with 190 μL of the selective media
(30 μg/mL kanamycin, 0.3% rhamnose, appropriate β-lactamase) and inoculated with 10 μL of
the 1-hour subculture. Preliminary results (data not shown) indicated that the β-lactamase clone
growth curves should be performed at the following concentrations: ampicillin (16 μg/mL),
carbenicillin (16 μg/mL), ceftazidime (8 μg/mL), aztreonam (8 μg/mL), and imipenem (2
μg/mL). These concentrations are half of the concentration used to determine antibiotic
resistance by the Clinical Laboratory Standards Institute (74). This is relevant since
approximately 80 μL of media was lost to evaporation over the course of the growth curve. The
plates were then incubated in a BioTek Synergy HT Microplate Reader at 37 ℃. OD600 readings
were taken after a brief shaking every 30 minutes over a 10.5-hour growth period. The growth
curves were also performed on the parent strain (K. pneumoniae 1300761) in LB with the
previously indicated antibiotics. Each growth curve was measured in duplicate, and the
experiment was repeated three times.
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TABLE 2: PCR primers for the cloning of β-lactamase genes found in Klebsiella pneumoniae
1300761.
bla gene
Forward Primer
Reverse Primer
CMY-6

CTX-M-15

NDM-4

OXA-1

SHV-11

TEM-1

cagctctagaggagGATTTCATGATGA

cagcgtcgacGCCTCATCGTCAGTT

AAAAATCGTTATGCTGC

ATTGCAGC

cagctctagaggaggAATCCCATGGTT

cagcgtcgaCGCTATTACAAACCGT

AAAAAATCACTGC

CGGTG

cagctctagaggaggAACTTGATGGAA

cagcgtcgacGTCAGCCATGGCTCA

TTGCCCAATATTATG

GCGC

cagctctagaggaggCTTATTATGAAA

cagcgtcgacGGGTTGGGCGATTTT

AACACAATACATATCAACTTCGC

GCCATTAG

cagctctagaggagGTGGTTATGCGTT

cagcgtcgacGGGTTAGCGTTGCCA

ATATTCGCCTGTGT

G

cagctctagaggaggAAGAGTATGAGT

cagcgtcgacTTGGTCTGACAGTTA

ATTCAACATTTTCGTGTC

CCAATGCTTAATC

Restriction site Ribosome binding site
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Statistical analysis
A two-way ANOVA in conjunction with Fisher’s Least Significant Difference test was
used to compare all time points against the control. Significance was determined if P<0.05.
When a β-lactamase clone reached absorbance levels significantly different than the control
before another in the same antibiotic, it was determined that the clone that reached significant
absorbance levels first is more efficient at hydrolyzing that β-lactam. When comparing growth
curves of a single β-lactamase in different growth conditions, if the growth curve in one
antibiotic reached significant absorbance levels at an earlier time point than another, it was
determined that that β-lactamase was more efficient at hydrolyzing the β-lactam that allowed
quicker growth.
RESULTS
Klebsiella pneumoniae 1300761 possesses six β-lactamase-encoding genes
Illumina sequencing produced 3,653,470 paired reads, and read processing reduced that
number to 3,370,288 with 80,534 retained as singletons, for approximately 150X coverage of the
genome. The average quality score of all reads is greater than 37, with an average length of 215.
Assembly generated 196 contigs larger than 1,000 bp, with an N50 of 238,732 and N75 of
112,412. The genome length is 5,972,622 bp. Annotation predicted 5,733 genes. Notably, 6
distinct bla genes were detected (Supplemental File 2) and confirmed by BLAST search [15] as
the following; blaCMY-6, blaCTX-M-15, blaNDM-4, blaOXA-1, blaSHV-11, and blaTEM-1. These bla genes
were then cloned into NEB5-α for further characterization.
Resistance profiles of β-lactamase clones
The control group in these Figs 2A-F is the pJG780 empty vector. When grown in
nutrient rich, non-selective LB, the only significant results were CTX-M-15, NDM-4 and OXA-

29

1; which had a significantly lower carrying capacity at 630 minutes (Fig 2A). When growth
occurred in LB ampicillin, all β-lactamases except CMY-6 reached growth levels significantly
different than the control by 300 minutes and by 630 minutes, CMY-6 also reached significant
levels (Fig 2B). In LB carbenicillin, all β-lactamases were at significant levels by 300 minutes,
and CMY-6 after 630 minutes (Fig 2C). In LB ceftazidime, NDM growth was evident by 300
minutes and CTX-M-15 by 630 minutes (Fig 2D). CTX-M-15 was the only β-lactamase that
hydrolyzed aztreonam, and significant levels were reached by 630 minutes (Fig 2E). NDM-4 was
the only β-lactamase that hydrolyzed imipenem, with growth observed by 300 minutes, but not
reaching significant levels until 630 minutes (Fig 2F). Complete growth curves are reported in
Fig S1, raw data in Table S1.
β-lactam preferences for a single β-lactamase
In these comparisons, the growth curve for pJG780 grown in ampicillin was used as a
negative control (Figs 3A-G). As expected, pJG780 only grew in LB, and attained growth levels
significantly different from the negative control by 300 minutes (Fig 3A). CMY-6 was able to
grow in ampicillin, and carbenicillin, however, this clone grew slowly in ampicillin, reaching
growth levels different than the control by 630 minutes (Fig 3B). CTX-M-15 grew in all
antibiotics except imipenem and growth was observed in ceftazidime by 630 minutes, but not yet
above background levels. By 300 minutes growth was evident in ampicillin and carbenicillin and
by 630 minutes for aztreonam (Fig 3C). NDM-4 grew in all antibiotics, except aztreonam.
Ampicillin, carbenicillin and ceftazidime reached significance by 300 minutes and imipenem by
630 minutes. (Fig 3D). OXA-1, SHV-11, and TEM-1 only grew in ampicillin and carbenicillin,
reaching significant levels in each case by 300 minutes (Fig 3E-H). Complete growth curves can
be found in Fig S2, raw data in Table S1.
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FIGURE 7: Growth curves grouped by growth conditions.
A) Nonrestrictive LB broth. B) Ampicillin. C) Carbenicillin. D) Ceftazidime. E) Aztreonam. F)
Imipenem. *P<0.05 **P<0.01, ***P<0.001, ****P<0.0001.
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FIGURE 8: Growth curves of the β-lactamase clones.
The clones were grown for 630 minutes, and the OD600 was measured every 30 minutes. A) The
pJG780 empty vector control strain. B) The CMY-6 clone. C) The CTX-M-15 clone. D) The
NDM-4 clone. E) The OXA-1 clone. F) The SHV-11 clone. G) The TEM-1 clone. H) The parent
strain K. pneumoniae 1300761. *P<0.05 **P<0.01, ***P<0.001, ****P<0.0001.
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Growth of the parent strain K. pneumoniae 1300761 is not inhibited by any β-lactam
tested
The two-way ANOVA indicated that antibiotic has no significant impact on growth, even
though individual time points may have randomly showed significance from the LB control (i.e.
imipenem at 630 minutes) (Fig 3H). Additionally, the lack of a significant lag phase when this
isolate was introduced to antibiotic-containing media, indicated that these genes are
constitutively expressed in K. pneumoniae 1300761.
DISCUSSION
The antibiotic crisis is reaching a crescendo as nosocomial bacteria acquire resistance to
the common, and last resort, antibiotics. Furthermore, it appears that individually, these bla
genes may not pose a large threat, as the fitness provided is relatively weak (i.e. imipenem,
ceftazidime, aztreonam). But there appears to be a synergistic effect as they are combined, and
that the additional resistance factors Klebsiella possesses (truncated porins, multi-drug efflux
pumps) aid greatly in its resistance. At the concentrations assayed, it seems that NDM-4 is
superior to CTX-M-15 as a cephalosporinase. Interestingly, it also appears that the
cephalosporinase CTX-M-15 provides a greater fitness advantage to aztreonam (a monobactam)
than ceftazidime (a cephalosporin). Finally, CMY-6 provides a better degree of fitness when
grown in ampicillin then carbenicillin. Tblahis result is interesting, and several blaCMY genes
have been shown to hydrolyze cephalosporins at aztreonam at high concentrations (76, 77).
Another path that could shed greater light on fitness provided by these various β-lactamases
would be to perform competition assays between them in the various antibiotics. Additionally,
this strategy could also help characterize the differences between the various carbapenemases.
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In conclusion, this study helps us understand that these organisms may acquire redundant
genes for the synergism acquired. This synergism provides the parent strain enhanced fitness in
antibiotics such as aztreonam and imipenem, where only one of the antibiotics hydrolyzes it, but
the parent strain grows normally. Additionally, this disparity in growth curve statistics may also
indicate that the passive resistance mechanisms (i.e. efflux pumps, altered porins) play a more
substantial role in resistance than previously thought, and they should receive more concentrated
attention.
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SUMMARY
This thesis provides only a starting point for further investigation. Much is still needed to
fully characterize these plasmids, and a greater surveillance of carbapenem-resistance plasmids is
needed to create a more comprehensive picture. Furthermore, several points are identified in
chapter 1 that can be exploited by small molecule inhibition to limit or eliminate the spread of
these plasmids. Additionally, there is a wealth of data available for the Escherichia coli and
Klebsiella pneumoniae carbapenem resistant isolates. This data could be mined for numerous
points of interest and conclusions made.
Second, the assay set up in chapter two could be used to assess the level of fitness
provided by the various carbapenemases. Additionally, as mention in chapter 2, competition
assays between these strains would also help determine if a fitness advantage is provided by the
β-lactamase activity, or if metabolic costs of producing the β-lactamase are a detriment to fitness.
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APPENDIX A
TABLE 3: Key Words used to characterize CR-plasmid gene content.

Antimicrobial Resistance

Categories

Key Word

Python Regular Expression

aac

aac

aad

aad

aminoglyco*

aminoglyco[^\s]

aph

aph

arr-

arr-

arsa

ars[a-dhr]

arsb

"

arsc

"

arsd

"

arsh

"

arsr

"

arsen*

arsen[^\s]

bleomycin

bleomycin

catr

catr

chloramphenicol

chloramphenicol

cmea

cme[abc]

cmeb

"

cmec

"
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copper

copper

dfra

(?:[^a-z]|^)dfra(?:$|[^a-z])

efflux pump

efflux pump

flor

flor

fluoroquino*

fluoroquino[^\s]

folp

(?:[^a-z]|^)folp(?:$|[^a-z])

macrolide

macrolide

mercur*

mercur[^\s]

mph

mph

multidrug

multidrug

ncra

(?:[^a-z]|^)ncr[a-c,y](?:$|[^a-z])

ncrb

"

ncrc

"

ncry

"

nickel resistant

(?:sulfonamide|trimethoprim|nickel)[
-]resistant

nirb

(?:[^a-z]|^)nirb(?:$|[^a-z])

sulfonamide resistant

"

trimethoprim resistant

"

pcoa

pco[a-ers]

pcob

"
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pcoc

"

pcod

"

pcoe

"

pcor

"

pcos

"

qace

qace

resistance

resistance

rifampin

rifamp(?:in|icin)

sila

sil[abcefprs]

silb

"

silc

"

sile

"

silf

"

silp

"

silr

"

sils

"

silver

silver

streptomycin

streptomycin

sul

(?:[^a-z]|^)sul[12](?:$|[^a-z])

teller*

teller[^\s]
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Antimicrobial Resistance,Beta-lactamase

tera

ter[abcfw-z](?:$|[^a-z])

terb

"

terc

"

terf

"

terw

"

terx

"

tery

"

terz

"

tetr

tetr(?:$|[^a]|acycline)

ampr

(?:^|[^p])ampr

beta lactam*

beta[ -]lactam[^\s]

beta-lactam*

"

bla

(?:^|[^p])bla

cephalosporin*

cephalosporin[^\s]

cmy-

(?:^|[^p])cmy-

ctx-

(?:^|[^p])ctx-

dha-

(?:^|[^p])dha-

oxa-

(?:^|[^p])oxa-

oxacillin*

oxacillin[^\s]

penicillin*

penicillin[^\s]
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Plasmid Transfer

Antimicrobial Resistance, Betalactamase, Beta-lactamase
Special

sfo-

(?:^|[^p])sfo-

shv-

(?:^|[^p])shv-

tem-

(?:^|[^p])tem-

carbapenem*

carbapenem[^\s]

imp not (impa or impb or impc)

(?:^|[^b-z])imp(?:$|[^abc])

kpc

(?:^|[^b-z])kpc

ndm

(?:^|[^b-z])ndm

vim

(?:^|[^b-z])vim

conjuga*

conjuga[^\s]

fertility inhibition

fertility inhibition

fino

fino

icm*

icm[^\s]

moba

mob[a-e]

mobb

"

mobc

"

mobd

"

mobe

"

pili*

pili[^\s]

pilus

pilus

pilx

pilx
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secretion system

secretion system

tivb*

tivb[^\s]

traa

tra[a-rtuwxy](?:$|[^a-z])

trab

"

trac

"

trad

"

trae

"

traf

"

trag

"

trah

"

trai

"

traj

"

trak

"

tral

"

tram

"

tran

"

trao

"

trap

"

traq

"

trar

"
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Toxin/Antitoxin
System

trat

"

trau

"

traw

"

trax

"

tray

"

trba

trb[a-gilm]

trbb

"

trbc

"

trbe

"

trbf

"

trbg

"

trbi

"

trbl

"

trbm

"

type iv

type[ -]iv

type-iv

"

vir* not virulence

vir[^ugo\s]

abrb

abrb

cbta

cbta

ccda

ccd[ab]

52

DNA
Maintenance/Modification

ccdb

"

hica

hica

higa

hig[ab]

higb

"

hokg

hokg

pard

par[de]

pare

"

pemi

pem[ik]

pemk

"

relb

rel[be]

rele

"

stbd

stb[de]

stbe

"

toxi*

(?:^|[^a-z]|anti)toxi[^\s]

yafo

yafo

chromosome

chromosome

dna

dna

eex

eex

entry exclusion

entry exclusion

exca

exca
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helicase

helicase

integrase

integrase

kfra

kfra

kora

kor[ab]

korb

"

methylase

methylase

nucleoti*

nucleoti[^\s]

para

par[ab]

parb

"

plasmid

plasmid

recombinase (not serine or tyrosine
recombinase)

(?<!ser_|ine )recombinase

relaxase

relaxase

repa

repa

replication

replication

replication protein

replication protein

ruma

ruma

single-strand binding protein

single-strand binding protein

ssb

ssb

topb

topb

topoisomerase

topoisomerase
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Hypothetical Genes

Mobile Genetic Elements

DNA
Maintenance/Modification,
DNA
Maintenance/Modification
Special

trfa

trfa

uvr*

uvr[^\s]

vagc

vag[cd]

vagd

"

muca

muc[ab]

mucb

"

polymerase

polymerase

umuc

umu[cd]

umud

"

ista

ist[ab](?:$|[^a-z0-9])

istb

"

resolvase

resolvase

reverse transcriptase

reverse transcriptase

tnp

tnp

transpos*

transpos[^\s]

urf2

urf2

domain containing

domain[ -]containing

domain-containing

"

hypothetical

hypothetical

uncharacterized protein

uncharacterized protein
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Ignored

unknown function

unknown function

disrupted

disrupted

imperfect

imperfect

interrupted

interrupted

intron

intron

is(?:[a-z]{2}|)[0-9]{2,4}

is(?:[a-z]{2}|)[0-9]{2,4}

kl.pn.i3

kl\.pn\.i3

morpho

morpho

ncrna

ncrna

non functional

non[ -]?functional

non-functional

"

partial

partial

patho

patho

repeat region

repeat region

se.ma.*

se\.ma\.[\s]

truncated

truncated
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APPENDIX B
Supplementary Bioinformatics Methods
This is a more detailed explanation of the bioinformatics methods required for
incompatibility group/replicon typing and plasmid characterization. This will describe a step-bystep walkthrough of the process. Please note that most of these steps will be simple data
formatting. Also note that it would have been easier in some cases to combine multiple steps into
one. The choice to separate each piece of the process was for clarity and to enable another to
modify this process for their own purposes. For our work, all steps could be run interactively;
i.e., not requiring a high-performance computing (HPC) architecture. Our work was completed
on a machine running Red Hat Enterprise Linux.
Summary
This process begins with one fasta file and multiple GenBank files. The formats for these
files are described in steps 0 and 2, respectively. The fasta file contains the incompatibility group
sequences. In our work, this was a download of the PlasmidFinder v1.3 Enterobacteriaceae
database (64). The GenBank files contain one or more GenBank records in them, where each
record could itself be considered a GenBank file for a single accession number. Thus, these
GenBank files are concatenations of multiple GenBank records. Effectively, this is how we
grouped accessions of interest. The same accession may appear in multiple groupings. Note, if
you attempt to re-use our process with your own data and have GenBank files as a single file per
accession, combining them into groups will feel unnecessary. We began this way because that is
what we had to start with.
The results of the entire process are CSV files with information about each plasmid in a
group and a text file with summary statistics about each group. The file contains basic
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information (e.g., plasmid length), the incompatibility group(s) the plasmid best aligns to, and
some gene/function annotation based on key term searches of the GenBank file's CDS regions.
To accomplish this, each (input) group GenBank file is split into a single GenBank file per
accession and the sequences are extracted as fasta files. The sequence lengths are recorded and
these sequences are individually aligned (using the NCBI BLAST+ Suite (60, 63)) to the
incompatibility group sequences. After filtering out the "best" alignments, the incompatibility
group is determined and saved for later assimilation into the final outputs. The CDS regions are
extracted from the GenBank files and searched for key terms using regular expressions. Each key
term belongs to one or more categories. Matches in each category are counted and summarized
in the final output. For more details on this searching strategy, please see step #11. The key terms
are listed with their Python regular expression in Appendix A.
This summary concludes with an outline of the steps. Each step will be detailed, followed by
the references. The code in the detailed steps has, in many cases, been simplified. In other cases,
the code is several pages long and would be difficult to copy and paste effectively. Especially the
with Python code, readability suffers as lines wrap because a standard page is not wide enough to
contain some code statements on a single line. Accordingly, we encourage you to visit the online
repository for the code: https://github.com/ridgelab/plasmidCharacterization.
Outline of Steps
Step 0. Format Incompatibility Groups Fasta File
Step 1. Create Incompatibility Groups BLAST database
Step 2. Split Multi-Accession GenBank Files
Step 3. Extract ORIGIN Sequence from GB to Fasta
Step 4. Extract Group Lists
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Step 5. Blast Incompatibility Groups
Step 6. Subset BLAST Results by Coverage Cutoff of 60%
Step 7. Add Incompatibility Group Family as Column to BLAST Results
Step 8. Filter Best Matches in BLAST Results
Step 9. Extract Incompatibility Families
Step 10. Extract Plasmid Search Regions
Step 11. Identify Plasmid Matches
Step 12. Generate Plasmid CSVs
Step 13. Create CSVs from Plasmid CSVs
Step 14. Create Group Matches from Plasmid Matches
Step 15. Calculate Group Statistics from Group CSV

Step 0. Format Incompatibility Groups Fasta File
Input: Fasta file with incompatibility group sequences. Each sequence may be on one or
more lines. The headers might start with “Inc”.
Output: Same fasta file as the input, but sequences occur on only one line. Headers without
“Inc” now have “Inc” prepended.
Code:
Bash Command
awk -f formatIncGroupFasta.awk \
original_incomp-grp.fasta \
> incomp-grp.fasta

AWK Script (formatIncGroupFasta.awk)
#! /bin/awk -f
{
if ( $0 ~ /^>.+$/ ) {
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if ( NR != 1 ) {
printf "\n";
}
if ( $0 ~ /^>Inc.+$/ ) {
print $0;
}
else {
printf "%s%s\n", ">Inc", substr($0, 2);
}
}
else {
printf "%s", $0;
}
}
END {
printf "\n";
}

Step 1. Create Incompatibility Groups BLAST database
Input: Fasta file with incompatibility group sequences. Each sequence is on only one line.
The headers start with “>Inc”.
Output: BLAST database of the incompatibility group sequences.
Code:
Bash Command
makeblastdb \
-dbtype nucl \
-in incompatibility.fasta \
-input_type fasta \
-title incompatibility \
-parse_seqids \
-hash_index \
-out incompatibility \
-max_file_sz 2GB \
-logfile makeBlastDB.log

BLAST Software
NCBI (United States National Center for Biotechnology Information) BLAST+ Suite version
2.4.0 (60, 63).
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Step 2. Split Multi-Accession GenBank Files
Input: 1+ GenBank files, each with 1+ records. Each record is itself a GenBank file for a
single Accession. Thus, the multi-accession GenBank files are simply concatenations of
multiple single-accession GenBank files. Assume that these GenBank files are in a directory
called original_gb.
Output: One GenBank file for each accession. If the same accession exists in more than one
multi-accession file, assume they are the same and overwrite it. Assume that the output
GenBank files will be in a directory called plasmid_gb.
Code:
Bash Command
cd plasmid_gb
while read ifn
do
awk -f splitMultiGB.awk "${ifn}"
done < <(ls -1 original_gb/*.gb)

AWK Script (splitMultiGB.awk)
#! /bin/awk -f
BEGIN {
FS="[ ]+";
accession="";
ofn="";
}
{
if ($0 == "//" || $0 == "")
{
accession = "";
ofn = "";
}
else if ($1 == "LOCUS")
{
accession = $2;
ofn = accession ".gb";
print $0 > ofn;
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}
else
{
print $0 >> ofn;
}
}
END {
print "done splitting " FILENAME " by accession";
}

Step 3. Extract ORIGIN Sequence from GB to Fasta
Input: One GenBank file with a single accession in it. Assume it is in the directory
plasmid_gb

and it is named after the pattern ${ACCESSION}.gb.

Output: One Fasta file with the sequence from the ORIGIN section of the GenBank file. The
Fasta file has sequences that are each on only one line. It will be in the directory
plasmid_fasta.

Code:
Bash Command
while read ifn
do
ACCESSION=`basename "${ifn}" ".gb"`
awk -f extractOriginSeqFromGBtoFasta.awk \
"plasmid_gb/${ACCESSION}.gb" \
> "plasmid_fasta/${ACCESSION}.fasta"
done < <(ls -1 plasmid_gb/*.gb)

AWK Script (extractOriginSeqFromGBtoFasta.awk)
#! /bin/awk -f
BEGIN {
FS = "[ ]+";
origin_found = 0; # false
}
{
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if (origin_found)
{
sub(/ *[0-9]+ /, "", $0);
gsub(/ +/, "", $0);
printf toupper($0);
}
else if ($1 == "ORIGIN")
{
origin_found = 1; # true
print ">" gensub(/^(.+)\.gb$/, "\\1", "-1", gensub(/^.*\//,
"", "-1", FILENAME));
}
}
END {
printf "\n";
print "done extracting ORIGIN seq from " FILENAME " to fasta" >
"/dev/stderr";
}

Step 4. Extract Group Lists
Input: One GenBank file with a multiple accessions in it. Assume it is in the directory
original_gb

and it is named after the pattern ${GROUP}.gb.

Output: Multiple text files, each with the extension ".list". Each file is a line separated list of
accession numbers that make up the group. The files will be in a directory called groups
with the name ${GROUP}.list.
Code:
Bash Command
while read ifn
do
awk -f extractGroupLists.awk \
"${ifn}"
done < <(ls -1 original_gb/*.gb)

AWK Script (extractGroupLists.awk)
#! /bin/awk -f
BEGIN {
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FS="[ ]+";
accession="";
ofn="";
}
{
if (NR == 1)
{
ofn = gensub(/^(.+)\.gb$/, "\\1", "-1", gensub(/^.*\//, "", "1", FILENAME)) ".list";
}
if ($1 == "LOCUS")
{
accession = $2;
print accession >> ofn;
}
}
END {
print "done extracting accessions from " FILENAME;
}

Step 5. Blast Incompatibility Groups
Input: Fasta files. Each contains the sequence from a single accession. Assume they are in the
directory plasmid_fasta and they are named after the pattern ${ACCESSION}.fasta.
Input: The incompatibility groups BLAST database created in step #1. It is named
incompatibility.

Output: One tab-separated value file for each input file. Each file is a modified version of the
BLAST output format 6. The format is specified as seen using the -outfmt option with blastn.
The columns are as follows: qseqid, sseqid, pident, length, evalue, qframe, qlen, qstart, qend,
sframe, slen, sstart, send, qseq, and sseq. The files will be in a directory called
blast_results

and named after the pattern ${ACCESSION}_fmt6c.tsv. Note that a match

was not included in the output if the percent identity was <80%.
Code:
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Bash Command
THREADS=8
while read ifn
do
ACCESSION=`basename "${ifn}" ".fasta"`
blastn \
-query "${ifn}" \
-strand both \
-task blastn \
-db icompatibility \
-out blast_results/${ACCESSION}_fmt6c.tsv \
-outfmt "6 qseqid sseqid pident length evalue qframe
qlen qstart qend sframe slen sstart send qseq sseq" \
-num_threads ${THREADS} \
-perc_identity 80
done < <(ls -1 plasmid_fasta/*.fasta)

BLAST Software
NCBI (United States National Center for Biotechnology Information) BLAST+ Suite version
2.4.0 (60, 63).
Step 6. Subset BLAST Results by Coverage Cutoff of 60%
Input: Tab-separated value files. Each contains the results from blasting the sequence of a
single accession against the incompatibility groups BLAST database. Assume they are in the
directory blast_results and they are named after the pattern ${ACCESSION}_fmt6c.tsv.
Output: One tab-separated value file for each input file. Each file is a copy of its respective
input file except some results may be omitted if the coverage was less than 60%. The files
will be in a directory called blast_results and named after the pattern
${ACCESSION}_fmt6c_cov60.tsv.

Note that a new column was inserted as column number

14 (1-based indexing). The columns will now be as follows: qseqid, sseqid, pident, length,
evalue, qframe, qlen, qstart, qend, sframe, slen, sstart, send, scov, qseq, and sseq.
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Code:
Bash Command
while read ifn
do
ACCESSION=`basename "${ifn}" "_fmt6c.tsv"`
awk -f subCovCutoff60.awk \
"${ifn}" \
> "blast_results/${ACCESSON}_fmt6c_cov60.tsv"
done < <(ls -1 blast_results/*_fmt6c.tsv)

AWK Script (subCovCutoff60.awk)
#! /bin/awk -f
BEGIN {
FS="\t";
OFS="\t";
ORS="\n";
count=0;
}
{
# 4 = length, 11 = slen, scov = length / slen
scov = $4 / $11;
if (scov >= 0.6)
{
count += 1
# keep 1-13, add new column, keep 14-15 (will become 15-16)
for (i = 1; i <= 13; i++)
{
printf "%s", $i OFS;
}
printf "%f", scov OFS;
for (i = 14; i <= NF; i++)
{
printf "%s", $i (i == NF ? ORS : OFS);
}
}
}
END {
print FILENAME ": " count > "/dev/stderr";
}

Step 7. Add Incompatibility Group as Column to BLAST Results
Input: Tab-separated value files. Each contains the results from blasting the sequence of a
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single accession against the incompatibility groups BLAST database. It has an added column
with the subject coverage and has only records with coverage >60%. Assume they are in the
directory blast_results and they are named after the pattern
${ACCESSION}_fmt6c_cov60.tsv.

Output: One tab-separated value file for each input file. Each file is a copy of its respective
input file except that an additional column is added. This column has the family or root of the
incompatibility group from column #2 (sseqid). The files will be in a directory called
blast_results

and named after the pattern ${ACCESSION}_fmt6c_cov60_fam.tsv. Note

that a new column was inserted as column number 3 (1-based indexing). The columns will
now be as follows: qseqid, sseqid, fam, pident, length, evalue, qframe, qlen, qstart, qend,
sframe, slen, sstart, send, scov, qseq, and sseq.
Code:
Bash Command
while read ifn
do
ACCESSION=`basename "${ifn}" "_fmt6c_cov60.tsv"`
awk -f addFamCol.awk \
"${ifn}" \
> "blast_results/${ACCESSON}_fmt6c_cov60_fam.tsv"
done < <(ls -1 blast_results/*_fmt6c_cov60.tsv)

AWK Script (addFamCol.awk)
#! /bin/awk -f
BEGIN {
FS="\t";
OFS="\t";
ORS="\n";
}
{
# 2 = subject_id, keep 1-2, add new column, keep 3-16 (will become 4-
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17)
for (i = 1; i <= 2; i++)
{
printf "%s", $i OFS;
}
printf "%s", gensub(/^([^(_]+).*$/, "\\1", "-1", $2) OFS;
for (i = 3; i <= NF; i++)
{
printf "%s", $i (i == NF ? ORS : OFS);
}
}

Step 8. Filter Best Matches in BLAST Results
Input: Tab-separated value files. Each contains the results from blasting the sequence of a
single accession against the incompatibility groups BLAST database. It has two added
columns with the subject coverage (and has only records with coverage >60%) and family.
Assume they are in the directory blast_results and are named after the pattern
${ACCESSION}_fmt6c_cov60_fam.tsv.

Output: One tab-separated value file for each input file. Each file is a copy of its respective
input file except that some results are omitted. The “best” results are retained. “Best” is
defined as the result(s) with the highest percent identity and those that have percent identities
within only 1 percent of the highest one. The files will be in a directory called
blast_results

and named after the pattern ${ACCESSION}_fmt6c_cov60_fam_best.tsv.

As in the input file, the columns will be as follows: qseqid, sseqid, fam, pident, length,
evalue, qframe, qlen, qstart, qend, sframe, slen, sstart, send, scov, qseq, and sseq.
Code:
Bash Command
while read ifn
do
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ACCESSION=`basename "${ifn}" "_fmt6c_cov60_fam.tsv"`
python3 filterBestResults.py \
"${ifn}" \
> "blast_results/${ACCESSON}_fmt6c_cov60_fam_best.tsv"
done < <(ls -1 blast_results/*_fmt6c_cov60_fam.tsv)

Python Version
Python 3.6.4 (https://www.python.org).
Python Script (filterBestResults.py)
def handleArgs():
if len(sys.argv) != 3:
sys.stderr.write("\n\tERROR: You must provide 2
arguments\n\t\t1- input blast results cov60 fam\n\t\t2- output blast
results file\n\n")
sys.exit(1)
input_br = sys.argv[1]
output_br = sys.argv[2]
return input_br, output_br
# ==== #
# MAIN #
# ==== #
if __name__ == "__main__":
import sys
# handle args
ibrfn, obrfn= handleArgs()
# set some handy vars
records = [] # each line
per_ids = [] # percent identities (the 4th column)
with open(ibrfn, 'r') as ifd:
for line in ifd:
records.append(line)
per_ids.append(float(line.rstrip('\n').split('\t')[3]))
# figure out which ones to keep
keep = []
max_per_id = max(per_ids) if len(records) > 0 else 0.0
for i,per_id in enumerate(per_ids):
if abs(max_per_id - per_id) <= 1.0:
keep.append(i)
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# write output
with open (obrfn, 'w') as ofd:
for i in keep:
ofd.write(records[i])
# exit
sys.exit(0)

Step 9. Extract Incompatibility Families
Input: Tab-separated value files. Each contains the results from blasting the sequence of a
single accession against the incompatibility groups BLAST database. It has two added
columns with the subject coverage (and has only records with coverage >60%) and family.
Only the “best” results remain. Assume they are in the directory blast_results and are
named after the pattern ${ACCESSION}_fmt6c_cov60_fam_best.tsv.
Output: One file for each input file. Each file is a line-delimited list of incompatibility group
roots/families. The files will be in a directory called blast_results and named after the
pattern ${ACCESSION}_families.list.
Code:
Bash Command
while read ifn
do
ACCESSION=`basename "${ifn}"
"_fmt6c_cov60_fam_best.tsv"`
cut -f 3 "${ifn}" \
| sort \
| uniq \
> blast_results/"${ACCESSON}_families.list"
done < <(ls -1 blast_results/*_fmt6c_cov60_fam_best.tsv)

Step 10. Extract Plasmid Search Regions
Input: This Python program requires 3 inputs. 1- The accession number of the plasmid it will
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extract the search regions from. 2- The directory where the output will be placed. 3- The
directory where the GenBank file is located for that plasmid. We assume the GenBank file is
named after the pattern ${ACCESSION}.gb.
Output: One text file containing the lines from input GenBank file that will be searched using
the key terms. We assume the output file will be named after the following pattern:
${ACCESSION}_searchRegions.txt.

For convenience, it will also generate a copy of the

input GenBank file with shell color codes, marking the CDS regions in blue, the portions of
the CDS regions that will be included in green, and the portion of the CDS regions that will
not be searched in red. This file will have the same name as the .txt file, but will have the
extension .gb instead of .txt. Note that intended search space is to consider each CDS
region as a separate entity. However, only the following subsections of each CDS region are
to be considered: \function, \gene, \note, and \product.
Code:
Bash Command
while read ifn
do
ACCESSION=`basename "${ifn}" ".gb"`
python3 extractPlasmidSearchRegions.py \
"${ACCESSION}" \
plasmid_searchRegions \
plasmid_gb
done < <(ls -1 plasmid_gb/*.gb)

Python Version
Python 3.6.4 (https://www.python.org).
Python Script (extractPlasmidSearchRegions.py)
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# ========= #

# FUNCTIONS #
# ========= #
def handleArgs():
import sys
if len(sys.argv) != 4:
sys.stderr.write("\n\tERROR: You must provide 3
arguments\n\t\t1- plasmid accession\n\t\t2- output search regions
dir\n\t\t3- input gb dir\n\n")
sys.exit(1)
plasmid_accession = sys.argv[1]
output_search_regions_dir = sys.argv[2].rstrip('/')
input_gb_dir = sys.argv[3].rstrip('/')
return plasmid_accession, output_search_regions_dir, input_gb_dir
def parseGbFile(input_gb_fn, output_search_regions_fn, output_gb_fn):
with open (output_search_regions_fn, 'w') as osrd:
with open(output_gb_fn, 'w') as ogbd:
red = "\033[0;31m"
green = "\033[0;32m"
blue = "\033[0;34m"
no_color = "\033[0m"
with open(input_gb_fn, 'r') as ifd:
section_names = ( "assembly_gap", "CDS",
"gene", "misc_difference", "misc_feature", "misc_recomb",
"mobile_element", "ncRNA", "operon", "oriT", "primer_bind",
"protein_bind", "regulatory", "repeat_region", "rep_origin",
"sig_peptide", "source", "tRNA" )
subsection_names_of_interest = ( "function",
"gene", "note", "product" )
# skip from LOCUS to FEATURES
line = ifd.readline() # grab the first line
("LOCUS")
while line.rstrip('\n').lstrip(' ').split('
')[0] != "FEATURES":
ogbd.write(line)
line = ifd.readline()
# write then skip past FEATURES
ogbd.write(line)
line = ifd.readline()
# skip any lines necessary until CDS or ORIGIN
is found
tag_word = line.rstrip('\n').lstrip('
').split(' ')[0]
while tag_word != "ORIGIN" and tag_word !=
"CDS":
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ogbd.write(line)
line = ifd.readline()
tag_word = line.rstrip('\n').lstrip('
').split(' ')[0]
# First time: found ORIGIN or CDS. If ORIGIN,
we're done. If CDS, read through each CDS region, until ORIGIN.
# thereafter: found ORIGIN or CDS or other
section name. If ORIGIN, we're done. If CDS, read through each CDS
region, until ORIGIN. If section name, skip till ORIGIN or next CDS.
while tag_word != "ORIGIN":
# first time: this loop will be
skipped. Thereafter, if a section name (other than CDS), skip to next
CDS or ORIGIN.
while tag_word != "ORIGIN" and tag_word
!= "CDS":
ogbd.write(line)
line = ifd.readline()
tag_word =
line.rstrip('\n').lstrip(' ').split(' ')[0]
if tag_word == "CDS":
# write the CDS line
osrd.write(line)
ogbd.write(blue + line +
no_color)
else: # if tag_word == "ORIGIN":
break
# skip past the CDS line (guaranteed to
now have a CDS line)
line = ifd.readline()
tag_word = line.rstrip('\n').lstrip('
').split(' ')[0]
# read through important data and stop
at end of CDS (marked by next CDS or ORIGIN or other section name)
# first time: guaranteed inside a CDS
region. Note that a CDS line is NEVER *immediately* followed by another
section name line (at least in our data).
# thereafter: It could be anything
between the CDS and ORIGIN.
while tag_word != "ORIGIN" and tag_word
not in section_names:
if line.rstrip('\n').lstrip('
')[0] == '/': # it is a CDS subsection headerline
subsection_name =
line.strip().split('=')[0].lstrip('/').lower()
subsection =
'='.join(line.strip().split('=')[1:])
if subsection_name in
subsection_names_of_interest: # the subsection is one we care to look
in
osrd.write(line)
ogbd.write(green
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+ line + no_color)
if subsection[0]
== '"' and subsection[-1] != '"': # the subsection spans multiple lines
line =
ifd.readline()
tag_word
= line.rstrip('\n').lstrip(' ').split(' ')[0]
while
line.rstrip('\n')[-1] != '"': # keep searching to find the end of the
subsection of interest
osrd.write(line)
ogbd.write(green + line + no_color)
line = ifd.readline()
tag_word = line.rstrip('\n').lstrip(' ').split(' ')[0]
osrd.write(line)
ogbd.write(green + line + no_color)
line =
ifd.readline()
tag_word =
line.rstrip('\n').lstrip(' ').split(' ')[0]
else: # the subsection
is not one we care to look in
#if
len(subsection) < 1:
#
print("subsection len == 0")
#
print(line)
#
print(subsection_name)
#
print(subsection)
# simple version
that works, but doesn't write it all in red
#ogbd.write(line)
#line =
ifd.readline()
#tag_word =
line.rstrip('\n').lstrip(' ').split(' ')[0]
# uneccesary
version that actually makes it write it all in red
ogbd.write(red +
line + no_color)
if
len(subsection) and subsection[0] == '"' and subsection[-1] != '"': #
the subsection spans multiple lines
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line =
ifd.readline()
tag_word
= line.rstrip('\n').lstrip(' ').split(' ')[0]
while
line.rstrip('\n')[-1] != '"': # keep searching to find the end of the
subsection of interest
ogbd.write(red + line + no_color)
line = ifd.readline()
tag_word = line.rstrip('\n').lstrip(' ').split(' ')[0]
ogbd.write(red + line + no_color)
line =
ifd.readline()
tag_word =
line.rstrip('\n').lstrip(' ').split(' ')[0]
else: # it is not a CDS
subsection headerline
ogbd.write(line)
line = ifd.readline()
tag_word =
line.rstrip('\n').lstrip(' ').split(' ')[0]
# NOTE: the remainder of the file contains the
sequence data
ogbd.write(line) # write the ORIGIN
ogbd.write(ifd.read()) # write the rest of the
file (i.e., the sequence data)
# ==== #
# MAIN #
# ==== #
if __name__ == "__main__":
import sys
# handle args
plasmid_accession, output_search_regions_dir, input_gb_dir =
handleArgs()
# set some helpful vars
osrn = output_search_regions_dir + '/' + plasmid_accession +
"_searchRegions.txt"
ogbn = output_search_regions_dir + '/' + plasmid_accession +
"_searchRegions.gb"
igbn = input_gb_dir + '/' + plasmid_accession + ".gb"
#
get CDS info (Antimicrobial Resistance CDS (%) ... Total CDS)
parseGbFile(igbn, osrn, ogbn)
# exit
sys.exit(0)
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Step 11. Identify Plasmid Matches
Input: This Python program requires 3 inputs. 1- The accession number of the plasmid in
which it will identify matches. 2- The directory where the input search regions file is located.
3- The directory where the output matches will be placed. We assume the input search
regions file is named after the pattern ${ACCESSION}_searchRegions.txt.
Output: One tab-separated value file containing matches. We assume the output file will be
named after the following pattern: ${ACCESSION}_matches.tsv. The columns of the file are
as follows:
1. Ignored (True/False)
2. Categories (c1[,c2,…,cN])
3. Search Term
4. CDS Region
Column 1 is a simple flag denoting if the term was to be ignored. This could also be
determined based on the second column, but it was convenient to have a simple flag as its
own column. Column 2 contains the category (categories) that the search term belonged to.
Column 3 contains the regular expression used. Column 4 contains the CDS region that was
searched (all tabs and newlines were converted to \t (backslash and a t, not a tab) and \n
(backslash and an n, not a newline) to not interfere with the tab-separated value file format
and keep each record on a single line).
Search Strategy: The search terms are each part of one or more categories. It can belong to
multiple categories only if the categories are subsets of each other. Five principal categories
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exist, two of which have subcategories. The category structure is as follows:


Antimicrobial Resistance
o Beta-lactamase


Beta-lactamase Special



Toxin/Antitoxin System



DNA Maintenance/Modification
o DNA Maintenance/Modification Special



Mobile Genetic Elements



Hypothetical Genes

The strategy could be described as top-to-bottom, in-to-out; i.e., Antimicrobial Resistance is
more important that Toxin/Antitoxin System and Beta-lactamase Special is more important
than Beta-lactamase and Antimicrobial Resistance. The reason these are shown nested
instead of simply above their parents is because a match for a Beta-lactamase Special search
term will increment the count for not only itself, but also its parents. If no matches are found,
the CDS region being searched is classified as "Other". Some CDS regions will never be
searched for these terms if they first match a term in a special "Ignored" category. Provided a
CDS region is not to be ignored, it will be searched with Beta-lactamase Special terms, then
Beta-lactamase terms, then Antimicrobial Resistance Terms, then Toxin/Antitoxin System
terms, and so-forth, until a match is found (thus halting the search on this CDS region) or no
more search terms remain (it is assigned to the "Other" category). All CDS regions are
converted to lowercase before being searched as described. See Supplementary Table 1 for a
table of search terms.
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Code:
Bash Command
while read ifn
do
ACCESSION=`basename "${ifn}" "_searchRegions.txt"`
python3 identifyPlasmidMatches.py \
"${ACCESSION}" \
plasmid_searchRegions \
plasmid_matches
done < <(ls -1 plasmid_searchRegions/*_searchRegions.txt)

Python Version
Python 3.6.4 (https://www.python.org).
Python Script (identifyPlasmidMatches.py)
# ========= #
# FUNCTIONS #
# ========= #
def handleArgs():
import sys
if len(sys.argv) != 4:
sys.stderr.write("\n\tERROR: You must provide 3
arguments\n\t\t1- plasmid accession\n\t\t2- input search regions
dir\n\t\t3- output matches dir\n\n")
sys.exit(1)
plasmid_accession = sys.argv[1]
input_search_regions_dir = sys.argv[2].rstrip('/')
output_matches_dir = sys.argv[3].rstrip('/')
return plasmid_accession, input_search_regions_dir, output_matches_dir
def writeLineToMatchesFile(matches_fd, ignored, categories,
search_term, cds_search_region):
matches_fd.write(str(ignored) + '\t' + ','.join(categories) + '\t' +
search_term + '\t' +
convertCDSsearchRegionToOneLineStr(cds_search_region) + '\n')
def ignoreCDS(cds_search_region, matches_fd):
key_terms = [ r"truncated", r"interrupted", r"partial", r"disrupted",
r"intron", r"kl\.pn\.i3", r"se\.ma\.[\s]", r"morpho",
r"repeat region", r"patho", r"ncrna", r"imperfect",
r"non[ -]?functional", r"is(?:[a-z]{2}|)[0-9]{2,4}" ]
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return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, True, ["Ignored"])
def betaLactSpecialCopyNum(cds_search_region, matches_fd):
key_terms = [ r"(?:^|[^b-z])ndm", r"(?:^|[^b-z])imp(?:$|[^abc])",
r"(?:^|[^b-z])vim", r"(?:^|[^b-z])kpc", r"carbapenem[^\s]" ]
return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["Antimicrobial Resistance", "Beta-lactamase",
"Beta-lactamase Special"])
def betaLactSearch(cds_search_region, matches_fd):
if not betaLactSpecialCopyNum(cds_search_region, matches_fd):
key_terms = [ r"(?:^|[^p])bla", r"beta[ -]lactam[^\s]",
r"(?:^|[^p])oxa-",
r"(?:^|[^p])dha-", r"(?:^|[^p])sfo-", r"(?:^|[^p])shv", r"(?:^|[^p])tem-",
r"(?:^|[^p])ctx-", r"(?:^|[^p])ampr", r"(?:^|[^p])cmy", r"oxacillin[^\s]",
r"penicillin[^\s]", r"cephalosporin[^\s]" ]
return searchCdsRegionForKeyTerms(cds_search_region,
key_terms, matches_fd, False, ["Antimicrobial Resistance", "Betalactamase"])
else:
return True
def antimicrobResistSearch(cds_search_region, matches_fd):
if not betaLactSearch(cds_search_region, matches_fd):
key_terms = [ r"aac", r"aad", r"aph", r"arr-",
r"resistance", r"aminoglyco[^\s]", r"streptomycin",
r"chloramphenicol",
r"cme[abc]", r"catr", r"multidrug", r"efflux pump",
r"mercur[^\s]", r"teller[^\s]", r"arsen[^\s]", r"qace",
r"macrolide", r"mph", r"silver", r"copper",
r"flor", r"ter[abcfw-z](?:$|[^a-z])",
r"fluoroquino[^\s]", r"bleomycin",
r"tetr(?:$|[^a]|acycline)", r"pco[a-ers]", r"ars[adhr]", r"sil[abcefprs]",
r"(?:sulfonamide|trimethoprim|nickel)[ -]resistant",
r"(?:[^a-z]|^)folp(?:$|[^a-z])",
r"(?:[^a-z]|^)sul[12](?:$|[^a-z])", r"(?:[^az]|^)dfra(?:$|[^a-z])",
r"(?:[^a-z]|^)ncr[a-c,y](?:$|[^a-z])", r"(?:[^az]|^)nirb(?:$|[^a-z])", r"rifamp(?:in|icin)" ]
return searchCdsRegionForKeyTerms(cds_search_region,
key_terms, matches_fd, False, ["Antimicrobial Resistance"])
else:
return True
def plasmidTransferSearch(cds_search_region, matches_fd):
key_terms = [ r"conjuga[^\s]", r"pili[^\s]", r"pilus", r"type[ -]iv",
r"secretion system", r"fertility inhibition", r"tivb[^\s]",
r"icm[^\s]",
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r"tra[a-rtuwxy](?:$|[^a-z])", r"trb[a-gilm]", r"mob[a-e]",
r"fino",
r"vir[^ugo\s]", r"pilx" ]
return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["Plasmid Transfer"])
def toxinSearch(cds_search_region, matches_fd):
key_terms = [ r"(?:^|[^a-z]|anti)toxi[^\s]", r"stb[de]", r"hig[ab]",
r"cbta",
r"rel[be]", r"hica", r"yafo", r"ccd[ab]",
r"abrb", r"par[de]", r"pem[ik]", r"hokg" ]
return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["Toxin System"])
def dnaMaintSpecialCopyNum(cds_search_region, matches_fd):
key_terms = [ r"muc[ab]", "umu[cd]", "polymerase" ]
return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["DNA Maintenance", "DNA Maintenance Special"])
def dnaMaintSearch(cds_search_region, matches_fd):
if not dnaMaintSpecialCopyNum(cds_search_region, matches_fd):
key_terms = [ r"methylase", r"single-strand binding protein",
r"ssb", r"topb",
r"replication protein", r"kfra", r"kor[ab]", r"trfa",
r"helicase", r"dna", r"chromosome", r"entry exclusion",
r"eex", r"exca", r"nucleoti[^\s]", r"topoisomerase",
r"integrase", r"(?<!ser_|ine )recombinase",
r"replication", r"nuclease",
r"relaxase", r"plasmid", r"ruma", r"repa",
r"uvr[^\s]", r"par[ab]", r"vag[cd]" ]
return searchCdsRegionForKeyTerms(cds_search_region,
key_terms, matches_fd, False, ["DNA Maintenance"])
else:
return True
def mobileGeneticElementsSearch(cds_search_region, matches_fd):
key_terms = [ r"transpos[^\s]", r"reverse transcriptase", r"tnp",
r"ist[ab](?:$|[^a-z0-9])", r"resolvase", "urf2" ]
return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["Mobile Genetic Elements"])
def hypotheticalGenesSearch(cds_search_region, matches_fd):
key_terms = [ r"hypothetical", r"domain[ -]containing",
r"uncharacterized protein", r"unknown function" ]
return searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, False, ["Hypothetical Genes"])
def convertCDSsearchRegionToOneLineStr(cds_search_region):
return "\\n".join(list(map(lambda x: x.replace('\t',
"\\t").replace('\n', ""), cds_search_region)))
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def searchCDSRegion(cds_search_region, matches_fd):
# make cds_search_region all lowercase
cds_search_region = list(map(lambda x: x.lower(), cds_search_region))
# make all the search regions lowercase
if not ignoreCDS(cds_search_region, matches_fd):
if not antimicrobResistSearch(cds_search_region, matches_fd):
if not plasmidTransferSearch(cds_search_region,
matches_fd):
if not toxinSearch(cds_search_region,
matches_fd):
if not
dnaMaintSearch(cds_search_region, matches_fd):
if not
mobileGeneticElementsSearch(cds_search_region, matches_fd):
if not
hypotheticalGenesSearch(cds_search_region, matches_fd):
writeLineToMatchesFile(matches_fd, False, ["Other"], "NA",
cds_search_region)
def searchCdsRegionForKeyTerms(cds_search_region, key_terms,
matches_fd, ignored, categories):
import re
for search_sub_region in cds_search_region:
for key_term in key_terms:
if re.search(key_term, search_sub_region) is not None:
writeLineToMatchesFile(matches_fd, ignored,
categories, key_term, cds_search_region)
return True
return False
def parseSearchRegionFile(input_sr_fn, matches_fn):
import re
with open(input_sr_fn, 'r') as ifd:
with open(matches_fn, 'w') as mfd:
mfd.write("Ignored (True/False)\tCategories
(c1[,c2,...,cN])\tSearch Term\tCDS Region\n")
cds_search_region = []
# All data is important. Read through all CDS regions
separately and search through them.
# Each CDS region begins with CDS and ends with another
CDS record or the end of file
# grab first line (always a CDS line)
line = ifd.readline()
tag_word = line.rstrip('\n').lstrip(' ').split(' ')[0]
cds_search_region.append(line)
# grab the next line
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line = ifd.readline()
tag_word = line.rstrip('\n').lstrip(' ').split(' ')[0]
while line != "":
while line != "" and tag_word != "CDS":
cds_search_region.append(line)
line = ifd.readline()
tag_word = line.rstrip('\n').lstrip('
').split(' ')[0]
# search the region
searchCDSRegion(cds_search_region, mfd)
cds_search_region = []
# grab the next line
cds_search_region.append(line)
line = ifd.readline()
tag_word = line.rstrip('\n').lstrip('
').split(' ')[0]
# ==== #
# MAIN #
# ==== #
if __name__ == "__main__":
import sys
# handle args
plasmid_accession, input_search_regions_dir, output_matches_dir =
handleArgs()
# set some helpful vars
isrn = input_search_regions_dir + '/' + plasmid_accession +
"_searchRegions.txt"
mfn = output_matches_dir + '/' + plasmid_accession + "_matches.tsv"
# search the search regions file for matches
parseSearchRegionFile(isrn, mfn)
# exit
sys.exit(0)

Step 12. Generate Plasmid CSVs
Input: This Python program requires 5 inputs. 1- The accession number of the plasmid it will
generate a CSV file for. 2- The directory where the output CSV file is to be placed. 3- The
directory where the plasmid fasta file is located. We assume it is named after the pattern
${ACCESSION}.fasta.

4- The directory where the input plasmid matches file is located. We

assume it is named after the pattern ${ACCESSION}_matches.tsv. 5- The directory where
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the input incompatibility groups (derived from the BLAST results) are located. We assume it
is named after the pattern ${ACCESSION}_families.list.
Output: One comma-separated value file. It will be placed in the directory specified in the
input position 2. We assume the output file will be named after the following pattern:
${ACCESSION}.csv.

The columns of the file are as follows:

"Accession #", "Plasmid Length", "Antimicrobial Resistance CDS", "Antimicrobial
Resistance CDS %", "Beta-lactamase CDS", "Beta-lactamase CDS %", "Beta-lactamase
Special (Carbapenem*,IMP,KPC,NDM,VIM) Copy #", "Beta-lactamase Special
(Carbapenem*,IMP,KPC,NDM,VIM) Copy # % of Beta-lactamase", "Beta-lactamase
Special (Carbapenem*,IMP,KPC,NDM,VIM) Absent (Yes/No)", "Plasmid Transfer
CDS", "Plasmid Transfer CDS %", "Toxin/Antitoxin System CDS", "Toxin/Antitoxin
System CDS %", "Toxin/Antitoxin System Present (Yes/No)", "DNA
Maintenance/Modification CDS", "DNA Maintenance/Modification CDS %", "DNA
Maintenance/Modification Special (mucA,mucB,polymerase,umuC,umuD) Copy #",
"DNA Maintenance/Modification Special (mucA,mucB,polymerase,umuC,umuD) Copy
# % of DNA Maintenance/Modification", "DNA Maintenance/Modification Special
(mucA,mucB,polymerase,umuC,umuD) Copy # % of Total", "DNA
Maintenance/Modification Special (mucA,mucB,polymerase,umuC,umuD) Present
(Yes/No)", "Mobile Genetic Elements CDS", "Mobile Genetic Elements CDS %",
"Hypothetical Genes CDS", "Hypothetical Genes CDS %", "Other CDS", "Other CDS
%", "Total CDS", "Incompatibility Groups"
Code:
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Bash Command
while read ifn
do
ACCESSION=`basename "${ifn}" ".fasta"`
python3 generatePlasmidCSV.py \
"${ACCESSION}" \
plasmid_csv \
plasmid_fasta \
plasmid_matches \
blast_results
done < <(ls -1 plasmid_fasta/*.fasta)

Python Version
Python 3.6.4 (https://www.python.org).
Python Script (generatePlasmidCSV.py)
# ========= #
# FUNCTIONS #
# ========= #
def handleArgs():
import sys
if len(sys.argv) != 6:
sys.stderr.write("\n\tERROR: You must provide 5
arguments\n\t\t1- plasmid accession\n\t\t2- output csv dir\n\t\t3input fasta dir\n\t\t4- input matches dir\n\t\t5- input incompatibility
groups blast output dir\n\n")
sys.exit(1)
plasmid_accession = sys.argv[1]
output_csv_dir = sys.argv[2].rstrip('/')
input_fasta_and_length_dir = sys.argv[3].rstrip('/')
input_matches_dir = sys.argv[4].rstrip('/')
input_incompatibility_groups_blast_output_dir =
sys.argv[5].rstrip('/')
return plasmid_accession, output_csv_dir, input_fasta_and_length_dir,
input_matches_dir, input_incompatibility_groups_blast_output_dir
def CSVify(some_str):
return '"' + some_str + '"'
def getPlasmidLength(input_length_fn):
with open(input_length_fn, 'r') as ifd:
return int(ifd.readline().rstrip('\n'))
def getRegionCounts(categories):
cats = [ "Antimicrobial Resistance", "Beta-lactamase", "Beta-lactamase
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Special",
"Plasmid Transfer", "Toxin System", "DNA Maintenance",
"DNA Maintenance Special", "Mobile Genetic Elements",
"Hypothetical Genes", "Other" ]
counts = [0] * len(cats)
category_counts = {}
for category in sorted(categories):
if not category in category_counts:
category_counts[category] = 0
category_counts[category] += 1
for i,cat in enumerate(cats):
counts[i] = category_counts[cat] if cat in category_counts
else 0
return counts
def updateCDScounts(cds_counts, cds_region_counts):
for i,cds_region_count in enumerate(cds_region_counts):
cds_counts[i] += cds_region_count
return cds_counts
def parseMatchesFile(matches_fn):
import re
with open(matches_fn, 'r') as ifd:
cds_counts = [0] * 10 # 10 CDS related columns in output
# skip past the TSV header line
ifd.readline()
# grab first data line
line = ifd.readline()
while line != "":
fields = line.rstrip('\n').split('\t')
ignore = True if fields[0] == "True" else False
categories = fields[1].split(',')
key_term = fields[2]
cds_search_region = fields[3]
if not ignore:
cds_counts = updateCDScounts(cds_counts,
getRegionCounts(categories) )
# grab the next line
line = ifd.readline()
tag_word = line.rstrip('\n').lstrip(' ').split(' ')[0]
return cds_counts

85

def getPercentOfTotal(count, total):
if total:
return count / total
else:
return "NA"
def convertCdsInfoToOutputStr(antimicrob_resist_cds_count,
beta_lact_cds_count, beta_lact_special_copy_num,
plasmid_transfer_cds_count, \
toxin_cds_count, dna_maint_cds_count,
dna_maint_special_copy_num, mobile_genetic_elements_cds_count, \
hypothetical_genes_cds_count, other_cds_count):
# initialize output list (will eventually become a giant string). Each
item will need to be easily converted to a string using str.
output = []
# find the total num of cds regions
total_cds_count = sum((antimicrob_resist_cds_count,
plasmid_transfer_cds_count, toxin_cds_count, \
dna_maint_cds_count, mobile_genetic_elements_cds_count,
hypothetical_genes_cds_count, other_cds_count))
# append columns to output
#
antimicrob resist (w/ beta lact)
#
antimicrob resist
output.append(antimicrob_resist_cds_count) # count
output.append(getPercentOfTotal(antimicrob_resist_cds_count,
total_cds_count)) # percent of total
#
beta lact
output.append(beta_lact_cds_count) # count
output.append(getPercentOfTotal(beta_lact_cds_count, total_cds_count))
# percent of total
#
special copy num
output.append(beta_lact_special_copy_num) # count
output.append(getPercentOfTotal(beta_lact_special_copy_num,
beta_lact_cds_count)) # percent of beta lact
output.append(getPercentOfTotal(beta_lact_special_copy_num,
total_cds_count)) # percent of total
output.append("No" if beta_lact_special_copy_num else "Yes") # absent
(Yes/No)
#
plasmid transfer
output.append(plasmid_transfer_cds_count) # count
output.append(getPercentOfTotal(plasmid_transfer_cds_count,
total_cds_count)) # percent of total
#
toxin system
output.append(toxin_cds_count) # count
output.append(getPercentOfTotal(toxin_cds_count, total_cds_count)) #
percent of total
output.append("Yes" if toxin_cds_count else "No") # present (Yes/No)
#
dna maint
output.append(dna_maint_cds_count) # count
output.append(getPercentOfTotal(dna_maint_cds_count, total_cds_count))
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# percent of total
#
special copy num
output.append(dna_maint_special_copy_num) # count
output.append(getPercentOfTotal(dna_maint_special_copy_num,
dna_maint_cds_count)) # percent of dna maint
output.append(getPercentOfTotal(dna_maint_special_copy_num,
total_cds_count)) # percent of total
output.append("Yes" if dna_maint_special_copy_num else "No") # present
(Yes/No)
#
mobile genetic elements
output.append(mobile_genetic_elements_cds_count) # count
output.append(getPercentOfTotal(mobile_genetic_elements_cds_count,
total_cds_count)) # percent of total
#
hypothetical genes
output.append(hypothetical_genes_cds_count) # count
output.append(getPercentOfTotal(hypothetical_genes_cds_count,
total_cds_count)) # percent of total
#
other (/unknown)
output.append(other_cds_count) # count
output.append(getPercentOfTotal(other_cds_count, total_cds_count)) #
percent of total
#
total
output.append(total_cds_count) # count
# convert all elements to str, join by ",", and add leading and
trailing "
output = CSVify("\",\"".join(list(map(str, output))))
# return
return output
def getIncompatibilityGroups(input_incompatibility_groups_fn):
with open(input_incompatibility_groups_fn, 'r') as ifd:
return [line.rstrip('\n') for line in ifd]
# ==== #
# MAIN #
# ==== #
if __name__ == "__main__":
import sys
# handle args
plasmid_accession, output_csv_dir, input_fasta_and_length_dir,
input_matches_dir, input_incompatibility_groups_blast_output_dir =
handleArgs()
# set
ocn =
ifn =
iln =
mfn =

some helpful vars
output_csv_dir + '/' + plasmid_accession + ".csv"
input_fasta_and_length_dir + '/' + plasmid_accession + ".fasta"
input_fasta_and_length_dir + '/' + plasmid_accession + ".length"
input_matches_dir + '/' + plasmid_accession + "_matches.tsv"
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iign = input_incompatibility_groups_blast_output_dir + '/' +
plasmid_accession + "_families.list"
csv_header = [ "Accession #",
"Plasmid Length",
"Antimicrobial Resistance CDS", "Antimicrobial Resistance CDS
%",
"Beta-lactamase CDS","Beta-lactamase CDS %", "Beta-lactamase
Special (Carbapenem*,IMP,KPC,NDM,VIM) Copy #", "Beta-lactamase Special
(Carbapenem*,IMP,KPC,NDM,VIM) Copy # % of Beta-lactamase", "Betalactamase Special (Carbapenem*,IMP,KPC,NDM,VIM) Copy # % of Total",
"Beta-lactamase Special (Carbapenem*,IMP,KPC,NDM,VIM) Absent (Yes/No)",
"Plasmid Transfer CDS", "Plasmid Transfer CDS %",
"Toxin/Antitoxin System CDS", "Toxin/Antitoxin System CDS %",
"Toxin/Antitoxin System Present (Yes/No)",
"DNA Maintenance/Modification CDS", "DNA
Maintenance/Modification CDS %", "DNA Maintenance/Modification Special
(mucA,mucB,polymerase,umuC,umuD) Copy #", "DNA Maintenance/Modification
Special (mucA,mucB,polymerase,umuC,umuD) Copy # % of DNA
Maintenance/Modification", "DNA Maintenance/Modification Special
(mucA,mucB,polymerase,umuC,umuD) Copy # % of Total", "DNA
Maintenance/Modification Special (mucA,mucB,polymerase,umuC,umuD)
Present (Yes/No)",
"Mobile Genetic Elements CDS", "Mobile Genetic Elements CDS
%",
"Hypothetical Genes CDS", "Hypothetical Genes CDS %",
"Other CDS", "Other CDS %",
"Total CDS",
"Incompatibility Groups" ]
# get necessary information
#
get CSV Header
csv_header_output_str = CSVify("\",\"".join(csv_header))
#
get plasmid accession #
plasmid_accession_output_str = CSVify(plasmid_accession)
#
get plasmid length
plasmid_length = getPlasmidLength(iln)
plasmid_length_output_str = CSVify(str(plasmid_length))
#
get CDS info (Antimicrobial Resistance CDS (%) ... Total CDS)
cds_info = parseMatchesFile(mfn)
cds_info_output_str = convertCdsInfoToOutputStr(*cds_info)
#
get incompatibility groups
incompatibility_groups = getIncompatibilityGroups(iign)
incompatibility_groups_output_str =
CSVify(','.join(incompatibility_groups)) if len(incompatibility_groups)
> 0 else CSVify("NA")
# write output
with open (ocn, 'w') as ocd:
# csv header line
ocd.write(csv_header_output_str + '\n') # csv header
# csv data line
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ocd.write(plasmid_accession_output_str + ',') # accession #
ocd.write(plasmid_length_output_str + ',') # plasmid length
ocd.write(cds_info_output_str + ',') # CDS info (Antimicrobial
Resistance CDS (%) ... Total CDS)
ocd.write(incompatibility_groups_output_str + '\n') #
incompatibility groups
# exit
sys.exit(0)

Step 13. Create CSVs from Plasmid CSVs
Input: The inputs required are the group list files that contain the plasmids in each group (see
step #4) and the individual plasmid CSVs (see step #12). The group list files are assumed to
be in the directory groups and named after the pattern ${GROUP}.list. The plasmid CSVs
are assumed to be in the plasmid_csv directory and named after the pattern
${ACCESSION}.csv.

Output: One comma-separated value file containing the same header line as all the plasmid
CSVs and a concatenation of the non-header lines from the plasmid CSVs. We assume the
output file will be in the directory group_csv and will be named after the following pattern:
${GROUP}.csv.

Code:
Bash Command
while read ifn
do
GROUP=`basename "${ifn}" ".list"`
ofn="group_csv/${GROUP}.csv"
# get and write a header
hfn=plasmid_csv/`head -q -n 1 "${ifn}"`".csv"
head -q -n 1 "${hfn}" > "${ofn}"
# get and write the non-headers lines
nhfns=`cat "${ifn}" | sed -r 's,^(.+)$,plasmid_csv/\1.csv,' |
tr '\n' ' '`
tail -q -n +2 ${nhfns} >> "${ofn}"
done < <(ls -1 groups/*.list)
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sed Note
sed must be GNU (https://www.gnu.org) sed. -r does not enable extended regular
expression syntax with BSD (http://www.bsd.org) sed.

Step 14. Create Group Matches from Plasmid Matches
Note that this step is not technically necessary to generate the desired output (the group CSV
files (step #13) and the group statistics files (step #15)). This is really for convenience in
inspecting results.
Input: The inputs required are the group list files that contain the plasmids in each group (see
step #4) and the individual plasmid matches (see step #11). The group list files are assumed
to be in the directory groups and named after the pattern ${GROUP}.list. The plasmid
matches are assumed to be in the plasmid_matches directory and named after the pattern
${ACCESSION}_matches.tsv.

Output: One text file containing the matches for the group. We assume the output file will be
in the directory group_matches and will be named after the following pattern:
${GROUP}_matches.tsv.

Code:
Bash Command
while read ifn
do
GROUP=`basename "${ifn}" ".list"`
ofn="group_matches/${GROUP}_matches.tsv"
fns=`cat "${ifn}" | sed -r
's,^(.+)$,plasmid_matches/\1_matches.tsv,' | tr '\n' ' '`
head -q -n 1 ${fns} | head -n 1 > "${ofn}"
tail -q -n +2 ${fns} >> "${ofn}"
done < <(ls -1 groups/*.list)
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sed Note
sed must be GNU (https://www.gnu.org) sed. -r does not enable extended regular
expression syntax with BSD (http://www.bsd.org) sed
Step 15. Calculate Group Statistics from Group CSV
Input: This Python program requires 2 inputs. 1- The CSV file for a group. Here, we show
the CSV files in the directory group_csv, named after the pattern ${GROUP}.csv. 2- The
output statistics file for the group. Here, we show the statistics files in the directory
group_stats,

named after the pattern ${GROUP}.stats.

Output: One text file named as described in position 2 of the input to the Python program.
That file is formatted as follows:
GROUP_NAME
===
Total # of Plasmids: ##
Incompatibility Groups Structure:
Inc.
Plasmid
Size
Group
Count
Mean
IncGrp1
#
#.###
IncGrp2
#
######.###
.
.
.
IncGrpN
#
#####.###

Size
St. Dev.
#.###
#####.###

####.###

Plasmids Summary:
Min: ####
Max: ######
Median: #####
Mean: ######.###
St. Dev.: ######.###
Key Words Structure:
Key
Word
anti_microb_resist
anti_microb_resist_not
beta_lact
beta_lact_not
plasmid_transfer
plasmid_transfer_not

Plasmid
Count
##
#
##
#
##
#

Size
Mean
######.###
######.###
######.###
######.###
######.###
#####.###

Size
St. Dev.
######.###
######
######.###
######
######.###
#####.###
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toxin
toxin_not
dna_maint
dna_maint_not
mob_gen_elem
mob_gen_elem_not
hypo_genes
hypo_genes_not
other
other_not

##
##
##
#
##
#
##
#
##
#

######.###
#####.###
######.###
######.###
######.###
######.###
######.###
######.###
######.###
######.###

#####.###
######.###
######.###
######
######.###
######.###
######.###
######
######.###
######.###

Plasmid Structure:
This information is already reported in the CSV file: GROUP_NAME.csv

Code:
Bash Command
while read gfn
do
GROUP=`basename "${gfn}" ".list"`
ifn="group_csv/${GROUP}.csv"
ofn="group_stats/${GROUP}.stats"
python3 calcGroupCSVstats.py\
"${ifn}" \
"${ofn}"
done < <(ls -1 groups/*.list)

Python Version
Python 3.6.4 (https://www.python.org).
Python Script (calcGroupCSVstats.py)
#############
# FUNCTIONS #
#############
def handleArgs(args, sefd, sexit):
if len(args) != 3:
sefd.write("\n\tERROR: Incorrect arguments\n\t\t1- input group
csv file\n\t\t2- output text file\n\n")
sexit(1)
ifn = sys.argv[1]
ofn = sys.argv[2]
return ifn, ofn
def writeIncGroupsStructure(ofd, inc_groups):
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output = []
sizes = []
header1 = ("Inc.", "Plasmid", "Size", "Size")
header2 = ("Group", "Count", "Mean", "St. Dev.")
output.append(header1)
sizes.append(tuple(map(len, output[-1])))
output.append(header2)
sizes.append(tuple(map(len, output[-1])))
for inc_group in sorted(inc_groups.keys()):
if inc_group != "NA":
lengths = inc_groups[inc_group]
count = len(lengths)
mean = count
st_dev = 0
if count > 1:
mean = stats.mean(lengths)
st_dev = stats.stdev(lengths)
output.append((inc_group, str(count),
"{0:.3f}".format(mean), "{0:.3f}".format(st_dev)))
sizes.append(tuple(map(len, output[-1])))
c0 = 0
c1 = 0
c2 = 0
c3 = 0
for size in sizes:
if size[0] >
c0 =
if size[1] >
c1 =
if size[2] >
c2 =
if size[3] >
c3 =

c0:
size[0]
c1:
size[1]
c2:
size[2]
c3:
size[3]

ofd.write("Incompatibility Groups Structure:\n")
for o,s in zip(output,sizes):
ofd.write('\t')
ofd.write(o[0] + ' ' * (c0 - s[0] + 3))
ofd.write(o[1] + ' ' * (c1 - s[1] + 3))
ofd.write(o[2] + ' ' * (c2 - s[2] + 3))
ofd.write(o[3] + ' ' * (c3 - s[3] + 3))
ofd.write('\n')
def getGroupStructureMeanStr(lengths):
if len(lengths) > 0:
return "{0:.3f}".format(stats.mean(lengths))
else:
return "NA"
def getGroupStructureStDevStr(lengths):
if len(lengths) > 1:
return "{0:.3f}".format(stats.stdev(lengths))
elif len(lengths) < 1: # == 0
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return "NA"
else: # == 1
return str(lengths[0])
def writeGroupStructure(ofd, all_group_structure_fields):
# set up the group structure arrays (to be populated with plasmid
lengths)
anti_microb_resist = []
anti_microb_resist_not = []
beta_lact = []
beta_lact_not = []
plasmid_transfer = []
plasmid_transfer_not = []
toxin = []
toxin_not = []
dna_maint = []
dna_maint_not = []
mob_gen_elem = []
mob_gen_elem_not = []
hypo_genes = []
hypo_genes_not = []
other = []
other_not = []
# extract the information and load it into the group structure arrays
for group_structure_fields in all_group_structure_fields:
# if three is a count, add it. else add it to the not. We're
adding the length.
length = group_structure_fields[0]
anti_microb_resist_count = group_structure_fields[1]
beta_lact_count = group_structure_fields[2]
plasmid_transfer_count = group_structure_fields[3]
toxin_count = group_structure_fields[4]
dna_maint_count = group_structure_fields[5]
mob_gen_elem_count = group_structure_fields[6]
hypo_genes_count = group_structure_fields[7]
other_count = group_structure_fields[8]
if anti_microb_resist_count:
anti_microb_resist.append(length)
else:
anti_microb_resist_not.append(length)
if beta_lact_count:
beta_lact.append(length)
else:
beta_lact_not.append(length)
if plasmid_transfer_count:
plasmid_transfer.append(length)
else:
plasmid_transfer_not.append(length)
if toxin_count:
toxin.append(length)
else:
toxin_not.append(length)
if dna_maint_count:
dna_maint.append(length)
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else:
dna_maint_not.append(length)
if mob_gen_elem_count:
mob_gen_elem.append(length)
else:
mob_gen_elem_not.append(length)
if hypo_genes_count:
hypo_genes.append(length)
else:
hypo_genes_not.append(length)
if other_count:
other.append(length)
else:
other_not.append(length)
# for each of the arrays, calc mean & st. dev., write to file
#
calc
anti_microb_resist_mean_str =
getGroupStructureMeanStr(anti_microb_resist)
anti_microb_resist_stdev_str =
getGroupStructureStDevStr(anti_microb_resist)
anti_microb_resist_not_mean_str =
getGroupStructureMeanStr(anti_microb_resist_not)
anti_microb_resist_not_stdev_str =
getGroupStructureStDevStr(anti_microb_resist_not)
beta_lact_mean_str = getGroupStructureMeanStr(beta_lact)
beta_lact_stdev_str = getGroupStructureStDevStr(beta_lact)
beta_lact_not_mean_str = getGroupStructureMeanStr(beta_lact_not)
beta_lact_not_stdev_str = getGroupStructureStDevStr(beta_lact_not)
plasmid_transfer_mean_str = getGroupStructureMeanStr(plasmid_transfer)
plasmid_transfer_stdev_str =
getGroupStructureStDevStr(plasmid_transfer)
plasmid_transfer_not_mean_str =
getGroupStructureMeanStr(plasmid_transfer_not)
plasmid_transfer_not_stdev_str =
getGroupStructureStDevStr(plasmid_transfer_not)
toxin_mean_str = getGroupStructureMeanStr(toxin)
toxin_stdev_str = getGroupStructureStDevStr(toxin)
toxin_not_mean_str = getGroupStructureMeanStr(toxin_not)
toxin_not_stdev_str = getGroupStructureStDevStr(toxin_not)
dna_maint_mean_str = getGroupStructureMeanStr(dna_maint)
dna_maint_stdev_str = getGroupStructureStDevStr(dna_maint)
dna_maint_not_mean_str = getGroupStructureMeanStr(dna_maint_not)
dna_maint_not_stdev_str = getGroupStructureStDevStr(dna_maint_not)
mob_gen_elem_mean_str = getGroupStructureMeanStr(mob_gen_elem)
mob_gen_elem_stdev_str = getGroupStructureStDevStr(mob_gen_elem)
mob_gen_elem_not_mean_str = getGroupStructureMeanStr(mob_gen_elem_not)
mob_gen_elem_not_stdev_str =
getGroupStructureStDevStr(mob_gen_elem_not)
hypo_genes_mean_str = getGroupStructureMeanStr(hypo_genes)
hypo_genes_stdev_str = getGroupStructureStDevStr(hypo_genes)
hypo_genes_not_mean_str = getGroupStructureMeanStr(hypo_genes_not)
hypo_genes_not_stdev_str = getGroupStructureStDevStr(hypo_genes_not)
other_mean_str = getGroupStructureMeanStr(other)
other_stdev_str = getGroupStructureStDevStr(other)
other_not_mean_str = getGroupStructureMeanStr(other_not)
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other_not_stdev_str = getGroupStructureStDevStr(other_not)
#
write to file
ofd.write("Key Words Structure:\n")
#
output = []
sizes = []

create columned output

header1 = ("Key", "Plasmid", "Size", "Size")
header2 = ("Word", "Count", "Mean", "St. Dev.")
output.append(header1)
output.append(header2)
output.append( ( "anti_microb_resist", str(len(anti_microb_resist)),
anti_microb_resist_mean_str, anti_microb_resist_stdev_str ) )
output.append( ( "anti_microb_resist_not",
str(len(anti_microb_resist_not)), anti_microb_resist_not_mean_str,
anti_microb_resist_not_stdev_str ) )
output.append( ( "beta_lact", str(len(beta_lact)), beta_lact_mean_str,
beta_lact_stdev_str ) )
output.append( ( "beta_lact_not", str(len(beta_lact_not)),
beta_lact_not_mean_str, beta_lact_not_stdev_str ) )
output.append( ( "plasmid_transfer", str(len(plasmid_transfer)),
plasmid_transfer_mean_str, plasmid_transfer_stdev_str ) )
output.append( ( "plasmid_transfer_not",
str(len(plasmid_transfer_not)), plasmid_transfer_not_mean_str,
plasmid_transfer_not_stdev_str ) )
output.append( ( "toxin", str(len(toxin)), toxin_mean_str,
toxin_stdev_str ) )
output.append( ( "toxin_not", str(len(toxin_not)), toxin_not_mean_str,
toxin_not_stdev_str ) )
output.append( ( "dna_maint", str(len(dna_maint)), dna_maint_mean_str,
dna_maint_stdev_str ) )
output.append( ( "dna_maint_not", str(len(dna_maint_not)),
dna_maint_not_mean_str, dna_maint_not_stdev_str ) )
output.append( ( "mob_gen_elem", str(len(mob_gen_elem)),
mob_gen_elem_mean_str, mob_gen_elem_stdev_str ) )
output.append( ( "mob_gen_elem_not", str(len(mob_gen_elem_not)),
mob_gen_elem_not_mean_str, mob_gen_elem_not_stdev_str ) )
output.append( ( "hypo_genes", str(len(hypo_genes)),
hypo_genes_mean_str, hypo_genes_stdev_str ) )
output.append( ( "hypo_genes_not", str(len(hypo_genes_not)),
hypo_genes_not_mean_str, hypo_genes_not_stdev_str ) )
output.append( ( "other", str(len(other)), other_mean_str,
other_stdev_str ) )
output.append( ( "other_not", str(len(other_not)), other_not_mean_str,
other_not_stdev_str ) )
for o in output:
sizes.append( tuple(map(len, o)))
c0 = 0
c1 = 0
c2 = 0
c3 = 0
for size in sizes:
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if size[0]
c0
if size[1]
c1
if size[2]
c2
if size[3]
c3

>
=
>
=
>
=
>
=

c0:
size[0]
c1:
size[1]
c2:
size[2]
c3:
size[3]

#
actually write
for o,s in zip(output,sizes):
ofd.write('\t')
ofd.write(o[0] + ' ' *
ofd.write(o[1] + ' ' *
ofd.write(o[2] + ' ' *
ofd.write(o[3] + ' ' *
ofd.write('\n')

to file
(c0
(c1
(c2
(c3

-

s[0]
s[1]
s[2]
s[3]

+
+
+
+

3))
3))
3))
3))

########
# MAIN #
########
if __name__ == "__main__":
import sys
import statistics as stats
ifn, ofn = handleArgs(sys.argv, sys.stderr, sys.exit)
group_name = '.'.join(ifn.strip().split('/')[-1].split('.')[:-1])
with open(ofn, 'w') as ofd:
# write the groupname title to the output
ofd.write(group_name + '\n' + '=' * len(group_name) + '\n')
# parse the input file and extract necessary information
with open(ifn, 'r') as ifd:
# skip past header line
ifd.readline()
# set some handy vars
total_number_of_plasmids = 0
plasmid_lengths = []
all_inc_groups = {}
all_group_structure_fields = []
# loop through each plasmid_record (line) in the input
file
for plasmid_record in ifd:
# increment the total num of plasmids (one
plasmid exists per line)
total_number_of_plasmids += 1
# split the record into its 28 separate
columns/fields
fields =
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plasmid_record.rstrip('\n').rstrip('"').lstrip('"').split("\",\"")
plasmid_accession = fields[0].strip('"')
plasmid_length = int(fields[1].strip('"'))
inc_groups = fields[28].strip('"').split(',')
group_structure_fields = tuple(map(lambda
field: int(field.strip('"')), (fields[1], fields[2], fields[4],
fields[10], fields[12], fields[15], fields[21], fields[23],
fields[25])))
# capture length information
plasmid_lengths.append(plasmid_length)
# capture info about inc groups
for inc_group in inc_groups:
if inc_group not in all_inc_groups:
all_inc_groups[inc_group] = []
all_inc_groups[inc_group].append(plasmid_length)
# capture info about group structure
all_group_structure_fields.append(group_structure_fields)
# write stuff to the output file
#
total number of plasmids
ofd.write("Total # of Plasmids: " +
str(total_number_of_plasmids) + '\n')
ofd.write('\n') # extra newline
#
inc groups structure
writeIncGroupsStructure(ofd, all_inc_groups)
ofd.write('\n') # extra newline
#
group plasmids size
ofd.write("Plasmids Summary:\n")
ofd.write("\t
Min: " + str(min(plasmid_lengths)) + '\n')
ofd.write("\t
Max: " + str(max(plasmid_lengths)) + '\n')
ofd.write("\t Median: " + str(stats.median(plasmid_lengths))
+ '\n')
ofd.write("\t
Mean: " +
"{0:.3f}".format(stats.mean(plasmid_lengths)) + '\n')
ofd.write("\tSt. Dev.: " +
"{0:.3f}\n".format(stats.stdev(plasmid_lengths)) if
len(plasmid_lengths) > 1 else '0' + '\n')
ofd.write('\n') # extra newline
#
group structure
writeGroupStructure(ofd, all_group_structure_fields)
ofd.write('\n') # extra newline
#
plasmid structure
ofd.write("Plasmid Structure:\n")
ofd.write("\tThis information is already reported in the CSV
file: " + ifn.split('/')[-1] + '\n')
ofd.write('\n') # extra newline
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APPENDIX C
TABLE 4: CR-plasmid accession numbers
CP008933
KX214669
KX214670
KX214671
KP873171
CP010881
CP025626
KT362706
MF353156
AB616660
AB759690
AP012055
AP012208
AP013064
AP018137
AP018138
AP018139
AP018141
AP018142
AP018143
AP018144
AP018146
AP018147
AP018454
AP018455
CP003224
CP003997
CP004366
CP004367
MF344563
MF344564
MF344565
MF344566
MF344567
MF344574
MF511773
MF547507
MF547508
MF547509
MF547510
MF547511
MF582638
MF679143
MF679147
MG049738
MG053313
MG271839
MG516907
KC543497
KY296095

CP006661
CP006799
CP012902
CP012990
CP014757
CP015835
CP015991
CP016035
CP016402
CP016403
CP016921
CP017937
CP017981
CP018366
CP018426
CP018432
CP018436
CP018668
CP018669
CP018675
CP018817
CP018884
CP018887
CP018945
CP018949
CP018956
CP018959
CP018963
CP018968
MF042356
MF042357
MF042358
MF042359
MF133495
MF150120
MF156708
MF156709
MF156711
MF156713
MF168402
MF168403
MF168404
MF168405
MF168406
MF178139
MF344561
MF344562
MG516908
KC609322
KY494864

CP018974
CP018977
CP018981
CP018989
CP018992
CP018999
CP019001
CP019006
CP019010
CP019014
CP019017
CP019026
CP019053
CP019073
CP019774
CP020049
CP020056
CP020059
CP020066
CP020068
CP020075
CP020110
CP020119
CP020848
CP020854
CP020902
CP021177
CP021206
CP021210
KY882285
KY887590
KY887591
KY887594
KY887595
KY887596
KY930324
KY930325
KY978631
LT009688
LT009689
LT216438
LT838197
MF042350
MF042351
MF042352
MF042353
MF042354
MG516909
KC609323
KY630469

CP021534
CP021536
CP021546
CP021548
CP021682
CP021687
CP021692
CP021699
CP021709
CP021716
CP021720
CP021734
CP021738
CP021743
CP021750
CP021754
CP021756
CP021759
CP021778
CP021835
CP021860
CP021861
CP021881
CP021899
CP021900
CP021936
CP021941
CP021947
CP021952
KY093014
KY130431
KY270849
KY270850
KY271403
KY271413
KY271414
KY271415
KY288024
KY399972
KY399973
KY399974
KY399975
KY435936
KY463220
KY798505
KY798506
KY798507
MG516910
KP873172
MF168945

Accession #
CP021961
CP021962
CP022126
CP022574
CP022693
CP023488
CP023554
CP023871
CP023895
CP023910
CP023914
CP023923
CP023926
CP023928
CP023938
CP023942
CP023948
CP023952
CP023959
CP024039
CP024192
CP024522
CP024529
CP024557
CP024805
CP024818
CP024825
CP024828
CP024833
KX711880
KX756453
KX783439
KX783440
KX783441
KX786648
KX833071
KX868553
KX881941
KX928750
KX928751
KX928752
KX960109
KX960110
KY020154
KY041843
KY062156
KY093013
MG557998
KP975076
MF344578

CP024836
CP024840
CP025006
CP025009
CP025010
CP025039
CP025141
CP025144
CP025147
CP025148
CP025458
CP025463
CP025467
CP025468
CP025517
CP025710
CP025948
CP025952
CP025964
CP025965
CP026175
CP026179
CP026201
CP026204
CP026205
CP026394
CP026395
CP026401
CP026474
KU862632
KU886034
KU934011
KX023261
KX062091
KX094555
KX154765
KX236178
KX276209
KX348144
KX348145
KX348146
KX397572
KX447767
KX470734
KX507346
KX674681
KX683284
MG557999
KU578314

CP026577
CP026584
CP026589
CP026590
EU855787
EU855788
FJ628167
GU585907
GU595196
HF955507
HG969995
HG969996
HG969997
HG969998
HG969999
HQ451074
HQ589350
JF503991
JF714412
JF785549
JN157804
JN233705
JN420336
JN687470
JN861072
JQ349086
JQ364967
JQ824049
JQ837276
KU167609
KU295131
KU295132
KU295133
KU295134
KU295135
KU295136
KU302800
KU302801
KU302802
KU314941
KU318419
KU318421
KU647721
KU665641
KU665642
KU726588
KU761328
AM778842
KX169264

JX101693
JX104759
JX104760
JX193301
JX193302
JX283456
JX397875
JX424614
JX430448
JX442975
JX461340
JX988621
KC311431
KC405622
KC788405
KC845573
KC887916
KC887917
KC958437
KC999035
KF017315
KF182187
KF220657
KF220658
KF250428
KF295829
KF534788
KF623109
KF701335
KR559890
KR822247
KT148595
KT185451
KT345946
KT345947
KT725788
KT725789
KT982613
KT982615
KT982616
KT982618
KT989376
KT989598
KU051707
KU051708
KU051709
KU167608
CP011370
KX711879

KF732966
KF874496
KF874497
KF874498
KF874499
KF914891
KF954759
KF954760
KF976405
KF977034
KF992018
KF998104
KJ146687
KJ146688
KJ146689
KJ187751
KJ187752
KJ413946
KJ440075
KJ440076
KJ577613
KJ588779
KJ653815
KJ721789
KJ721790
KJ802404
KJ802405
KJ812998
KJ933392
KJ958926
KJ958927
KM400601
KM877517
KM977631
KP125892
KP345882
KP776609
KP868646
KP868647
KP893385
KP900015
KP987218
KR059864
KR091915
KR351290
KR559888
KR559889
KC189475
KX889311
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APPENDIX D
TABLE 5: Percent of plasmids belonging to each incompatibility group.
Percent of plasmids Inc Group
0.22% IncA/C
11.88% IncA/C2

Percent of plasmids Inc Group
13.68% IncN
0.67% IncN2

0.22% IncB/O/K/Z

0.67% IncN3

0.67% Col

0.22% IncP1

1.35% Col440I

0.90% IncP6

1.79% ColRNAI

1.35% IncQ1

4.71% IncFIA

0.22% IncQ2

12.78% IncFIB

8.97% IncR

19.73% IncFII

2.24% repA

2.24% IncHI1B
0.45% IncHI2

1.79% IncU
13.23% IncX3

0.45% IncHI2A

0.22% IncX4

0.22% IncI1

0.90% IncX5

0.90% IncI2

0.67% IncX6

2.69% IncL/M

0.90% IncY
7.62% Unclassified

(Note: Total is greater than 100% because some plasmids have multiple incompatibility
groups)
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APPENDIX E
TABLE 6: Relative abundance of incompatibility groups among carbapenemase-carrying
plasmids.
Supplementary Table 4: Relative abundance of incompatibility groups among carbapenemase-carrying plasmids.
Carbapenemase

Incompatibility Groups (Percent of plasmids)

Family

IncA/C

IncA/C2

IncB/O/K/Z

Col

Col440I

ColRNAI

IncFIA

IncFIB

IncFII

IncHI1B

IncHI2

KPC

0.0%

4.0%

0.0%

0.0%

2.5%

4.0%

5.6%

18.2%

20.2%

0.0%

0.0%

NDM

0.0%

17.9%

0.6%

0.0%

0.0%

0.0%

6.0%

10.7%

28.0%

6.0%

0.0%

IMP

0.0%

22.4%

0.0%

0.0%

0.0%

0.0%

0.0%

2.0%

2.0%

0.0%

4.1%

VIM

3.2%

16.1%

0.0%

9.7%

3.2%

0.0%

0.0%

6.5%

3.2%

0.0%

0.0%

IncHI2A

IncI1

IncI2

IncL/M

IncN

IncN2

IncN3

IncP1

IncP6

IncQ1

IncQ2

KPC

0.0%

0.0%

2.0%

2.5%

17.7%

0.0%

1.0%

0.5%

1.5%

1.5%

0.5%

NDM

0.0%

0.0%

0.0%

1.2%

3.0%

1.8%

0.0%

0.0%

0.0%

1.8%

0.0%

IMP

4.1%

2.0%

0.0%

10.2%

34.7%

0.0%

2.0%

0.0%

0.0%

0.0%

0.0%

VIM

0.0%

0.0%

0.0%

0.0%

12.9%

0.0%

0.0%

0.0%

3.2%

0.0%

0.0%

IncR

repA

IncU

IncX3

IncX4

IncX5

IncX6

IncY

NA

KPC

13.6%

5.1%

2.5%

5.6%

0.0%

1.5%

1.5%

1.5%

5.6%

NDM

4.8%

0.0%

0.0%

29.2%

0.6%

0.0%

0.0%

0.6%

2.4%

IMP

2.0%

0.0%

6.1%

0.0%

0.0%

2.0%

0.0%

2.0%

16.3%

VIM

12.9%

0.0%

0.0%

0.0%

0.0%

0.0%

0.0%

0.0%

35.5%

Note: Totals are greater than 100% because some plasmids carry more than one replicon type.
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